

Publications Department Radiotherapy UMCU, 2015-2019

2019

1. Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score. Post CCB, Kramer MCA, Smid EJ, van der Weide HL, Kleynen CE, Heesters MAAM, Verhoeff JJC. *Radiother Oncol.* 2019 Jan;130:156-163.
2. Commissioning of a water calorimeter as a primary standard for absorbed dose to water in magnetic fields. De Prez, L., de Pooter, J., Jansen, B., Woodings, S., Wolthaus, J., van Asselen, B., van Soest, T., Kok, J. and Raaymakers, B., 2019, *Phys Med Biol.*, 64, 035013.
3. Improved repeatability of dynamic contrast-enhanced MRI using the complex MRI signal to derive arterial input functions: a test-retest study in prostate cancer patients. Klawer EME, van Houdt PJ, Simonis FFJ, van den Berg CAT, Pos FJ, Heijmink SWTPJ, Isebaert S, Haustermans K, van der Heide UA. *Magn Reson Med.* 2019 May;81(5):3358-3369.
4. Assessment of Neurocognitive Impairment and Speech Functioning Before Head and Neck Cancer Treatment. Piai V, Prins JB, Verdonck-de Leeuw IM, Leemans CR, Terhaard CHJ, Langendijk JA, Baatenburg de Jong RJ, Smit JH, Takes RP, Kessels RPC. *JAMA Otolaryngol Head Neck Surg.* 2019 Jan 24.
5. Clinical value of (dedicated) 3 Tesla and 7 Tesla MRI for cT1 glottic carcinoma: A feasibility study. Van Egmond SL, Vonck BMD, Bluemink JJ, Pameijer FA, Dankbaar JW, Stegeman I, Philippens MEP, van den Berg CAT, Janssen LM, Terhaard CH. *Laryngoscope Invest Otolaryngol.* 2019 Jan 15;4(1):95-101.
6. Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial. Eekers DBP, Roelofs E, Cubillos-Mesias M, Niël C, Smeenk RJ, Hoeben A, Minken AWH, Granzier M, Janssens GO, Kaanders JHAM, Lambin P, Troost EGC. *Acta Oncol.* 2019 Jan;58(1):57-65.
7. A Systematic Review of Devices and Techniques that Objectively Measure Patients' Pain. Wagemakers SH, van der Velden JM, Gerlich AS, Hindriks-Keegstra AW, van Dijk JFM, Verhoeff JJC. *Pain Physician.* 2019 Jan;22(1):1-13.
8. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME. *Cancer Med.* 2019 Jan;8(1):190-199.
9. Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of ¹⁸F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting. van den Bosch S, Dijkema T, Philippens MEP, Terhaard CHJ, Hoebbers FJP, Kaanders JHAM, Oyen WJG. *Radiother Oncol.* 2019 Jan;130:39-45.
10. Intrafraction motion quantification and planning target volume margin determination of head-and-neck tumors using cine magnetic resonance imaging. Bruijnen T, Stemkens B, Terhaard CHJ, Lagendijk JJW, Raaijmakers CPJ, Tijssen RHN. *Radiother Oncol.* 2019 Jan;130:82-88.
11. Intrafraction Motion Management of Renal Cell Carcinoma With Magnetic Resonance Imaging-Guided Stereotactic Body Radiation Therapy. Prins FM, Stemkens B, Kerkmeijer LGW, Barendrecht MM, de Boer HJ, Voncken EPA, Lagendijk JJW, Tijssen RHN. *Pract Radiat Oncol.* 2019 Jan;9(1).
12. Prospective comparative study of MRI including diffusion-weighted images versus FDG PET-CT for the detection of recurrent head and neck squamous cell carcinomas after (chemo)radiotherapy. Driessen JP, Peltenburg B, Philippens MEP, Huijbregts JE, Pameijer FA, de Bree R, Janssen LM, Terhaard CHJ. *Eur J Radiol.* 2019 Feb;111:62-67.
13. Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma. Vaarwerk B, Schoot RA, Maurice-Stam H, Slater O, Hartley B, Saeed P, Gajdosova E, van den Brekel MW, Balm AJM, Hol MLF, van Jaarsveld S, Kremer LCM, Ronckers CM, Mandeville HC, Pieters BR, Gaze MN, Davila Fajardo R, Strackee SD, Dunaway D, Smeele LE, Chisholm JC, Caron HN, Grootkaspartsenhuis MA, Merks JHM. *Pediatr Blood Cancer.* 2019 Feb;66(2).
14. Physical activity levels of women with breast cancer during and after treatment, a comparison with the Dutch female population. Gal R, Monninkhof EM, Peeters PHM, van Gils CH, van den Bongard DHJG, Wendel-Vos GCW, Zuithoff NPA, Verkooijen HM, May AM. *Acta Oncol.* 2019 Feb 6:1-9.

15. Multiresolution radial MRI to reduce IDLE time in pre-beam imaging on an MR-Linac (MR-RIDDLE). Bruijnen T, Stemkens B, Lagendijk JJW, van den Berg CAT, Tijssen RHN. *Phys Med Biol.* 2019 Feb 27;64(5).
16. A coaxial RF applicator for ultra high field human MRI. Solomakha G, Andreychenko A, Raaijmakers A, van de Moortele PF, van den Berg CAT. *IEEE Trans BiomedEng.* 2019 Feb 1.
17. MRI-based tumor inter-fraction motion statistics for rectal cancer boost radiotherapy. Kleijnen JJE, van Asselen B, Van den Begin R, Intven M, Burbach JPM, Reerink O, Philippens MEP, de Ridder M, Lagendijk JJW, Raaymakers BW. *Acta Oncol.* 2019 Feb;58(2):232-236.
18. Potential benefit of MRI-guided IMRT for flank irradiation in pediatric patients with Wilms' tumor. Guerreiro F, Seravalli E, Janssens GO, van den Heuvel-Eibrink MM, Lagendijk JJW, Raaymakers BW. *Acta Oncol.* 2019 Feb;58(2):243-250.
19. The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients. Gregorowitsch ML, Ghedri A, Young-Afat DA, Bijlsma R, Baas IO, van Schaik-van de Mheen C, Agterof MJ, Goker E, Ten Bokkel Huinink D, van den Bongard HJGD, Verkooijen HM: UMBRELLA study group. *Breast Cancer res Treat* 2019; Feb 12.
20. Sparing the surgical area with stereotactic body radiotherapy for combined treatment of spinal metastases: a treatment planning Study. Versteeg AL, Hes J, van der Velden JM, Eppinga W, Kasperts N, Verkooijen HM, van Vulpen M, Oner FC, Seravalli E, Verlaan JJ. *Acta Oncol.* 2019 Feb;58(2):251-256.
21. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients. Gregorowitsch ML, Verkooijen HM, Houweling A, Fuhler N, Koelemij R, Schoenmaeckers EJP, Sier MF, Ernst MF, Witkamp AJ, Van Dalen T, Young-Afat DA, van den Bongard DHJG; UMBRELLA study group. *Radiother Oncol.* 2019 Feb;131:221-228.
22. Feasibility of MRI-only photon and proton dose calculations for pediatric patients with abdominal tumors. Guerreiro F, Koivula L, Seravalli E, Janssens GO, Maduro JH, Brouwer CL, Korevaar EW, Knopf AC, Korhonen J, Raaymakers BW. *Phys Med Biol.* 2019 Feb 25;64(5).
23. A dual-purpose MRI acquisition to combine 4D-MRI and dynamic contrast-enhanced imaging for abdominal radiotherapy planning. Stemkens B, Prins FM, Bruijnen T, Kerkmeijer LGW, Lagendijk JJW, van den Berg CAT, Tijssen RHN. *Phys Med Biol.* 2019 Mar 8;64(6).
24. Intersubject specific absorption rate variability analysis through construction of 23 realistic body models for prostate imaging at 7T. Melià EF, van den Berg CAT, Luijten PR, Raaijmakers AJE. *Magn Reson Med.* 2019 Mar;81(3):2106-2119.
25. Monte Carlo simulations of out-of-field skin dose due to spiralling contaminant electrons in a perpendicular magnetic field. Malkov VN, Hackett SL, van Asselen B, Raaymakers BW, Wolthaus JWH. *Med Phys.* 2019 Mar;46(3):1467-1477.
26. Monte Carlo simulations of out-of-field surface doses due to the electron streaming effect in orthogonal magnetic fields. Malkov VN, Hackett SL, Wolthaus JWH, Raaymakers BW, van Asselen B. *Phys Med Biol.* 2019 Feb 26.
27. On the accuracy and precision of PLANET for multiparametric MRI using phase-cycled bSSFP imaging. Shcherbakova Y, van den Berg CAT, Moonen CTW, Bartels LW. *Magn Reson Med.* 2019 Mar;81(3):1534-1552.
28. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study. Borggreve AS, van Rossum PSN, Mook S, Haj Mohammad N, van Hillegersberg R, Ruurda JP. *Eur J Surg Oncol.* 2019 Mar 27.
29. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Snaebjornsson P, Kuipers EJ, Bruno MJ, Dekker E, Meijer GA, de Boer JP, van Leeuwen FE, van Leerdam ME. *Cancer.* 2019 Mar 15;125(6):990-999.
30. Changes in cortical thickness and volume after cranial radiation treatment: A systematic review. Nagtegaal SHJ, David S, van der Boog ATJ, Leemans A, Verhoeff JJC. *Radiother Oncol.* 2019 Mar 6;135:33-42.
31. ypTON+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field. Schurink B, Seesing MFJ, Goense L, Mook S, Brosens LAA, Mohammad NH, Ruurda JP, Roeling TAP, Bleys RLAW, van Hillegersberg R. *Eur J Surg Oncol.* 2019 Mar;45(3):454-459.
32. Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro. Sadeghi N, Kok RJ, Bos C, Zandvliet M, Geerts WJC, Storm G, Moonen CTW, Lammers T, Deckers R. *Nanotechnology.* 2019 Mar 5;30(26).

33. Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II. Berger T, Seppenwoolde Y, Pötter R, Assenholt MS, Lindegaard JC, Nout RA, de Leeuw A, Jürgenliemk-Schulz I, Tan LT, Georg D, Kirisits C, Dumas I, Nesvacil N, Swamidas J, Hudej R, Lowe G, Hellebust TP, Menon G, Fokdal L, Tanderup K; EMBRACE Collaborative Group. *Int J Radiat Oncol Biol Phys.* 2019 Mar 21.
34. Change in patterns of failure after image-guided brachytherapy for cervical cancer: analysis from the RetroEMBRACE study. Tan LT, Pötter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, Gregory D, Petric P, Jürgenliemk-Schulz I, Gillham C, Van Limbergen E, Hoskin P, Tharavichitkul E, Villafranca E, Mahantshetty U, Kirisits C, Lindegaard J, Kirchheiner K, Tanderup K. *Int J Radiat Oncol Biol Phys.* 2019 Mar 30.
35. MRI commissioning of 1.5T MR-linac systems - a multi-institutional study. Tijssen RHN, Philippens MEP, Paulson ES, Glitzner M, Chugh B, Wetscherek A, Dubec M, Wang J, van der Heide UA. *Radiother Oncol.* 2019 Mar;132:114-120.
36. Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group. Hoeben BA, Carrie C, Timmermann B, Mandeville HC, Gandola L, Dieckmann K, Ramos Albiac M, Magelssen H, Lassen-Ramshad Y, Ondrová B, Ajithkumar T, Alapetite C, Balgobind BV, Bolle S, Cameron AL, Davila Fajardo R, Dietzsch S, Dumont Lecomte D, van den Heuvel-Eibrink MM, Kortmann RD, Laprie A, Melchior P, Padovani L, Rombi B, Scarzello G, Schwarz R, Seiersen K, Seravalli E, Thorp N, Whitfield GA, Boterberg T, Janssens GO. *Lancet Oncol.* 2019 Mar;20(3).
37. Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. Fokdal L, Tanderup K, Pötter R, Sturdza A, Kirchheiner K, Chargari C, Jürgenliemk-Schulz IM, Segedin B, Tan LT, Hoskin P, Mahantshetty U, Bruheim K, Rai B, Kirisits C, Lindegaard JC; EMBRACE Collaborative Group. *Int J Radiat Oncol Biol Phys.* 2019 Mar 15;103(4):887-894.
38. Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer. Kok JL, Teepen JC, van der Pal HJ, van Leeuwen FE, Tissing WJE, Neggers SJM, Loonen JJ, Louwerens M, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Jaspers MMW, van Santen HM, van der Heiden-van der Loo M, Janssens GO, Maduro JH, Bruggink AH, Jongmans MC, Kremer LCM, Ronckers CM; DCOG-LATER Study Group. *JAMA Oncol.* 2019 Mar 28.
39. MRI-guided ultrafocal HDR-brachytherapy for localised prostate cancer: median 4 year results of a feasibility study. Peters M, van Son MJ, Moerland MA, Kerkmeijer LGW, Eppinga WSC, Meijer RP, Lagendijk Ir JJW, Shah TT, Ahmed HU, van der Voort van Zijp JRN. *Int J Radiat Oncol Biol Phys.* 2019 Mar 26.
40. Individual lymph nodes: "See it and Zap it". Winkel D, Werensteijn-Honingh AM, Kroon PS, Eppinga WSC, Bol GH, Intven MPW, de Boer HCJ, Snoeren LMW, Hes J, Raaymakers BW, Jürgenliemk-Schulz IM. *ctRO.* March 2019.
41. Adaptive radiotherapy: The Elekta Unity MR-linac concept. Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett S, Werensteijn-Honingh AM, Intven MPW, Eppinga WSC, Tijssen RHN, Kerkmeijer LGW, de Boer HCJ, Mook S, Meijer GJ, Hes J, Willemsen-Bosman M, de Groot-van Breugel EN, Jürgenliemk-Schulz IM, Raaymakers BW. *ctRO.* April 2019.
42. Management of Nodal Disease in Advanced Cervical Cancer. Jürgenliemk-Schulz IM, Beriwal S, de Leeuw AAC, Lindegaard JC, Nomden CN, Pötter R, Tanderup K, Viswanathan AN, Erickson B. *Semin Radiat Oncol.* 2019 Apr;29(2):158-165.
43. Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra. Bril SI, Wendrich AW, Swartz JE, Wegner I, Pameijer F, Smid EJ, Bol GH, Pothen AJ, de Bree R. *Eur Arch Otorhinolaryngol.* 2019 Apr;276(4):1175-1182.
44. Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. de Rojas T, Clementel E, Giralt J, Cruz O, Boterberg T, Kortmann RD, Gaze MN, Moreno L, Janssens GO; SIOPE-Europe QUARTET Project and of the EORTC. *Eur J Cancer.* 2019 Apr 26;114:36-46.
45. Prognostic Value of Brain Metastasis Free Interval in Patients with Breast Cancer Brain Metastases. Hulsbergen AFC, Lamba N, Claes A, Kavouridis V, Lin NU, Smith TR, Verhoeff JJC, Broekman MLD. *World Neurosurg.* 2019 Apr 26.
46. Fiducial marker based intra-fraction motion assessment on cine-MR for MR-linac treatment of prostate cancer. de Muinck Keizer DM, Pathmanathan AU, Andreychenko A, Kerkmeijer LGW, van der Voort van Zyp JRN, Tree AC, van den Berg CAT, de Boer JCJ. *Phys Med Biol.* 2019 Apr 4;64(7).

47. Small Cell Carcinoma of the Esophagus: A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease. Jeene PM, Geijsen ED, Muijs CT, Rozema T, Aleman BMP, Muller K, Baas JM, Nuyttens JJ, Wouterse S, Braam PM, Oppedijk V, Ceha HM, Cnossen J, Spruit P, Bongers EM, Berbée M, Mook S, Hulshof MCCM. *Am J Clin Oncol*. 2019 Apr 22.
48. MRI artifact simulation for clinically relevant MRI sequences for guidance of prostate HDR brachytherapy. Beld E, Moerland MA, van der Voort van Zyp JRN, Viergever MA, Lagendijk JJW, Seevinck PR. *Phys Med Biol*. 2019 Apr 4.
49. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, Goense L, Mook S, Hartemink KJ, Snaebjornsson P, Ter Beek LC, Verheij M, Aleman BMP, Beets-Tan RGH, Bartels-Rutten A. *Br J Surg*. 2019 Apr;106(5):596-605.
50. Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. Seppenwoolde Y, Assenholt MS, Georg D, Nout R, Tan LT, Rumpold T, de Leeuw A, Jürgenliemk-Schulz I, Kirisits C, Pötter R, Lindegaard JC, Tanderup K; EMBRACE Collaborative Group. *Radiother Oncol*. 2019 Apr;133:149-155.
51. Health-related quality of life in rectal cancer patients undergoing neoadjuvant chemoradiation with delayed surgery versus short-course radiotherapy with immediate surgery: a propensity score-matched cohort study. Couwenberg AM, Burbach JPM, Intven MPW, Consten ECJ, Schiphorst AHW, Smits AB, Wijffels NAT, Heikens JT, Koopman M, van Grevenstein WMU, Verkooijen HM. *Acta Oncol*. 2019 Apr;58(4):407-416.
52. Robot-assisted Minimally Invasive Thoracoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial. van der Sluis PC, van der Horst S, May AM, Schippers C, Brosens LAA, Joore HCA, Kroese CC, Haj Mohammad N, Mook S, Vleggaar FP, Borel Rinkes IHM, Ruurda JP, van Hillegersberg R. *Ann Surg*. 2019 Apr;269(4):621-630.
53. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. Werensteijn-Honingh AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B, Bol GH, Brown KJ, Eppinga WSC, van Es CA, Glitzner M, de Groot-van Breugel EN, Hackett SL, Intven M, Kok JGM, Kontaxis C, Kotte AN, Lagendijk JJW, Philippens MEP, Tijssen RHN, Wolthaus JWH, Woodings SJ, Raaymakers BW, Jürgenliemk-Schulz IM. *Radiother Oncol*. 2019 May;134:50-54.
54. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. *Br J Radiol*. 2019 May; 92(1097).
55. Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Nomden CN, Pötter R, de Leeuw AAC, Tanderup K, Lindegaard JC, Schmid MP, Fortin I, Haie-Meder C, Mahantshetty U, Hoskin P, Segedin B, Bruheim K, Rai B, Huang F, Cooper R, Van Der Steen Banasik E, Van Limbergen E, Jürgenliemk-Schulz IM; EMBRACE Collaborative Group. *Radiother Oncol*. 2019 May;134:185-190.
56. Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance. Winkel D, Bol GH, Werensteijn-Honingh AM, Kiekebosch IH, van Asselen B, Intven MPW, Eppinga WSC, Raaymakers BW, Jürgenliemk-Schulz IM, Kroon PS. *phiRO*. 2019; 9: 58-64.
57. Comparing signal-to-noise ratio for prostate imaging at 7T and 3T. Steensma BR, Luttje M, Voogt IJ, Klomp DWJ, Luijten PR, van den Berg CAT, Raaijmakers AJE. *J Magn Reson Imaging*. 2019 May;49(5):1446-1455.
58. Patient reported outcomes after the treatment of early stage NSCLC with stereotactic body radiotherapy compared to surgery. L. Alberts, H.B. Wolff, E.A. Kastelijjn, F.J. Lagerwaard, F.N. Hofman, S.Y. El Sharouni, F.M.N.H. Schramel, V.M.H. Coupe. *Clinical Lung Cancer*, Accepted Date: 2 April 2019.
59. Adaptive radiotherapy: The Elekta Unity MR-linac concept. Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett S, Werensteijn-Honingh AM, Intven MPW, Eppinga WSC, Tijssen RHN, Kerkmeijer LGW, de Boer HCJ, Mook S, Meijer GJ, Hes J, Willemsen-Bosman M, de Groot-van Breugel EN, Jürgenliemk-Schulz IM, Raaymakers BW. *ctRO*, April 2019.
60. Recommendations for the organisation of care in paediatric radiation oncology across Europe: a SIOP Europe – ESTRO – PROS – CCI Europe collaborative project in the framework of the JARC. Janssens GO, Timmermann B, Laprie A, Mandeville H, Padovani L, Chargari C, Journy N, Kameric L, Kienesberger A, Brunhofer M, Kozhaeva O, Gasparotto C, Kearns P, Boterberg T, Lievens Y, Vassal G. *Eur J Cancer*. 2019 May;114:47-54.
61. Accuracy and precision of electrical permittivity mapping at 3T: the impact of three B+1 mapping techniques. Gavazzi S, van den Berg CAT, Sbrizzi A, Kok HP, Stalpers LJA, Lagendijk JJW, Crezee H, van Lier ALHMW. *Magn Reson Med*. 2019 Jun;81(6):3628-3642.

62. Image-guided adaptive radiotherapy in cervical cancer. Tan LTT, Tanderup K, Kirisits C, De Leeuw A, Nout R, Duke S, Seppenwoolde Y, Nesvacil N, Georg D, Kirchheiner K, Fokdal L, Sturdza A, Schmid M, Swamidas J, van Limbergen E, Haie-Meder C, Mahantshetty U, Jürgenliemk-Schulz I, Lindegaard JC, and Pötter R. *Seminars in Radiation Oncology* 2019; 29(3):284-298.
63. Cervical cancer apparent diffusion coefficient values during external beam radiotherapy. De Boer P, Mandija S, Werensteijn-Honingh AM, Van den Berg CAT, De Leeuw AAC, Jürgenliemk-Schulz IM. *Physics and Imaging in Radiation Oncology* 9 (2019) 77-82.
64. Implementation of state-of-the-art (chemo)radiation for advanced cervix cancer in the Netherlands: a quality improvement program. De Leeuw AAC, Nout RA, Van Leeuwen RGH, Mans A, Verhoef LG, Jürgenliemk-Schulz IM. *Technical Innovations&Patient support in Radiation Oncology* 9 (2019)1-7.
65. Direct measurement of ion chamber correction factors, k_Q and k_B , in a 7 MV MRI-linac. De Prez, L.A., Woodings, S.J., de Pooter, J.A., van Asselen, B., Wolthaus, J.W.H., Jansen, B.J. and Raaymakers, B., 2019, *Phys Med Biol.*, accepted.

2018

66. Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. Peters M, Kanthabalan A, Shah TT, McCartan N, Moore CM, Arya M, van der Voort van Zyp JR, Moerland MA, Hindley RG, Emberton M, Ahmed HU. *Urol Oncol.* 2018 Jan;36(1).
67. Local control in sinonasal malignant melanoma: Comparing conventional to hypofractionated radiotherapy. Lansu J, Klop WM, Heemsbergen W, Navran A, Al-Mamgani A, Langendijk JA, Kaanders JH, Terhaard C, Karakullukcu B, Hamming-Vrieze O. *Head Neck.* 2018 Jan;40(1):86-93.
68. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. Goense L, Heethuis SE, van Rossum PSN, Voncken FEM, Lagendijk JJW, Lam MGEH, Terhaard CH, van Hillegersberg R, Ruurda JP, Mook S, van Lier ALHMW, Lin SH, Meijer GJ. *Nucl Med Commun.* 2018 Jan;39(1):60-67.
69. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Pötter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B, Hoskin P, Bruheim K, Rai B, Huang F, Van Limbergen E, Schmid M, Nesvacil N, Sturdza A, Fokdal L, Jensen NBK, Georg D, Assenholt M, Seppenwoolde Y, Nomden C, Fortin I, Chopra S, van der Heide U, Rumpold T, Lindegaard JC, Jürgenliemk-Schulz I; EMBRACE Collaborative Group. *Clin Transl Radiat Oncol.* 2018 Jan 11;9:48-60.
70. Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. Gregorowitsch ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, van Gils CH, May AM, Verkooijen HM. *Breast Cancer Res Treat.* 2018 Jan;167(1):205-213.
71. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer. Maenhout M, van der Voort van Zyp JRN, Borot de Battisti M, Peters M, van Vulpen M, van den Bosch M, Moerland MA. *Brachytherapy.* 2018 Jan - Feb;17(1):68-77.
72. Characterization of a prototype MR-compatible Delta4 QA system in a 1.5 tesla MR-linac. de Vries JHW, Seravalli E, Houweling AC, Woodings SJ, van Rooij R, Wolthaus JWH, Lagendijk JJW, Raaymakers BW. *Phys Med Biol.* 2018 Jan 11;63(2).
73. Characterization of the first RF coil dedicated to 1.5 T MR guided radiotherapy. Hoogcarspel SJ, Zijlema SE, Tijssen RHN, Kerkmeijer LGW, Jürgenliemk-Schulz IM, Lagendijk JJW, Raaymakers BW. *Phys Med Biol.* 2018 Jan 11;63(2).
74. Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, van der Heide UA, Frank SJ, Nill S, Oelfke U, van Herk M, Li XA, Mittauer K, Ritter M, Choudhury A, Tree AC. *Int J Radiat Oncol Biol Phys.* 2018 Feb 1;100(2):361-373.
75. The use of a simultaneous integrated boost in spinal stereotactic body radiotherapy to reduce the risk of vertebral compression fractures: a treatment planning study. van der Velden JM, Hes J, Sahgal A, Hoogcarspel SJ, Philippens MEP, Eppinga WSC, Seravalli E. *Acta Oncol.* 2018 Sep;57(9):1271-1274.
76. Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. Heerkens HD, van Berkel L, Tseng DSJ, Monninkhof EM, van Santvoort HC, Hagendoorn J, Borel Rinkes IHM, Lips IM, Intven M, Molenaar IQ. *HPB (Oxford).* 2018 Feb;20(2):188-195.

77. PLANET: An ellipse fitting approach for simultaneous T(1) and T(2) mapping using phase-cycled balanced steady-state free precession. Shcherbakova Y, van den Berg CAT, Moonen CTW, Bartels LW. *Magn Reson Med*. 2018 Feb;79(2):711-722.
78. Systematic review of the diagnostic value of magnetic resonance imaging for early glottic carcinoma. van Egmond SL, Stegeman I, Pameijer FA, Bluemink JJ, Terhaard CH, Janssen LM. *Laryngoscope Investig Otolaryngol*. 2018 Feb 5;3(1):49-55.
79. Influence of tumor and microenvironment characteristics on diffusion-weighted imaging in oropharyngeal carcinoma: A pilot study. Swartz JE, Driessen JP, van Kempen PMW, de Bree R, Janssen LM, Pameijer FA, Terhaard CHJ, Philippens MEP, Willems S. *Oral Oncol*. 2018 Feb;77:9-15.
80. An 8-channel Tx/Rx dipole array combined with 16 Rx loops for high-resolution functional cardiac imaging at 7 T. *MAGMA*. Steensma BR, Voogt IJ, Leiner T, Luijten PR, Habets J, Klomp DWJ, van den Berg CAT, Raaijmakers AJE. 2018 Feb;31(1):7-18.
81. Fast quantitative MRI as a nonlinear tomography problem. Sbrizzi A, Heide OV, Cloos M, Toorn AV, Hoogduin H, Luijten PR, van den Berg CAT. *Magn Reson Imaging*. 2018 Feb;46:56-63.
82. Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer. Bulens P, Couwenberg A, Haustermans K, Debucquoy A, Vandecaveye V, Philippens M, Zhou M, Gevaert O, Intven M. *Radiother Oncol*. 2018 Mar;126(3):437-442.
83. Inter-observer agreement in GTV delineation of bone metastases on CT and impact of MR imaging: A multicenter study. Gerlich AS, van der Velden JM, Kotte ANTJ, Tseng CL, Fanetti G, Eppinga WSC, Kasperts N, Intven MPW, Pameijer FA, Philippens MEP, Verkooijen HM, Seravalli E. *Radiother Oncol*. 2018 Mar;126(3):534-540.
84. Performance of a PTW 60019 microDiamond detector in a 1.5 T MRI-linac. Woodings SJ, Wolthaus JWH, van Asselen B, de Vries JHW, Kok JGM, Lagendijk JJW, Raaijmakers BW. *Phys Med Biol*. 2018 Mar 8;63(5).
85. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. de Vries S, Schaapveld M, van Nimwegen FA, Józwiak K, Lugtenburg PJ, Daniëls LA, Roesink JM, van der Maazen RWM, Kok WEM, Aleman BMP, van Leeuwen FE. *Br J Cancer*. 2018 Mar 20;118(6):887-895.
86. Pancreatic gross tumor volume contouring on computed tomography (CT) compared with magnetic resonance imaging (MRI): Results of an international contouring conference. Hall WA, Heerkens HD, Paulson ES, Meijer GJ, Kotte AN, Knechtges P, Parikh PJ, Bassetti MF, Lee P, Aitken KL, Palta M, Myrehaug S, Koay EJ, Portelance L, Ben-Josef E, Erickson BA. *Pract Radiat Oncol*. 2018 Mar - Apr;8(2):107-115.
87. The accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments. van Stam MA, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, Horenblas S, Aaronson NK, Ruud Bosch JLH. *BJU Int*. 2018 Mar;121(3):405-414.
88. The impact of postoperative complications on health-related quality of life in older patients with rectal cancer; a prospective cohort study. Couwenberg AM, de Beer FSA, Intven MPW, Burbach JPM, Smits AB, Consten ECJ, Schiphorst AHW, Wijffels NAT, de Roos MAJ, Hamaker ME, van Grevenstein WMU, Verkooijen HM. *J Geriatr Oncol*. 2018 Mar;9(2):102-109.
89. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. *Lancet Oncol*. 2018 Mar;19(3):295-309.
90. Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. van Dijk SM, Heerkens HD, Tseng DSJ, Intven M, Molenaar IQ, van Santvoort HC. *HPB (Oxford)*. 2018 Mar;20(3):204-215.
91. Respiratory motion model based on the noise covariance matrix of a receive array. Andreychenko A, Denis de Senneville B, Navest RJM, Tijssen RHN, Lagendijk JJW, van den Berg CAT. *Magn Reson Med*. 2018 Mar;79(3):1730-1735.
92. Optimal High-Dose-Rate Brachytherapy Fractionation Scheme After Keloid Excision: A Retrospective Multicenter Comparison of Recurrence Rates and Complications. Bijlard E, Verduijn GM, Harmeling JX, Dehnad H, Niessen FB, Meijer OWM, Mureau MAM. *Int J Radiat Oncol Biol Phys*. 2018 Mar 1;100(3):679-686.

93. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. *Lancet Oncol*. 2018 Mar;19(3):295-309.
94. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial. Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. *Int J Radiat Oncol Biol Phys*. 2018 Apr 1;100(5):1133-1145.
95. Evaluation of Online Plan Adaptation Strategies for the 1.5T MR-linac Based on "First-In-Man" Treatments. Winkel D, Bol GH, Kiekebosch IH, Van Asselen B, Kroon PS, Jürgenliemk-Schulz IM, Raaymakers BW. *Cureus*. 2018 Apr 5;10(4).
96. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. Daamen LA, Groot VP, Heerkens HD, Intven MPW, van Santvoort HC, Molenaar IQ. *HPB (Oxford)*. 2018 Apr;20(4):297-304.
97. Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer. Van Son MJ, Peters M, Moerland MA, Noteboom JL, Eppinga WS, Davila Fajardo R, Lagendijk J, Van der Voort van Zyp JR. *Cureus*. 2018 Apr 5;10(4).
98. Does setup on rectal wall improve rectal cancer boost radiotherapy? Kleijnen JJE, van Asselen B, Intven M, Burbach JPM, Philippens MEP, Lagendijk JJW, Raaymakers BW. *Radiat Oncol*. 2018 Apr 4;13(1):61.
99. MR-based source localization for MR-guided HDR brachytherapy. Beld E, Moerland MA, Zijlstra F, Viergever MA, Lagendijk JJW, Seevinck PR. *Phys Med Biol*. 2018, Apr 5;63(8).
100. Target Volume Delineation Using Diffusion-weighted Imaging for MR-guided Radiotherapy: A Case Series of Laryngeal Cancer Validated by Pathology. Ligtenberg H, Schakel T, Dankbaar JW, Ruiter LN, Peltenburg B, Willems SM, Kasperts N, Terhaard CHJ, Raaijmakers CPJ, Philippens MEP. *Cureus*. 2018 Apr 11;10(4).
101. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Monninkhof EM, van Loon JW, van Vulpen M, Kerkmeijer LGW, Pos FJ, Hausermans K, van den Bergh L, Isebaert S, McColl GM, Smeenk RJ, Noteboom J, Walraven I, Peeters PHM, van der Heide UA. *Radiat Oncol*. 2018 Apr;127(1):74-80.
102. Early Tissue Effects of Stereotactic Body Radiation Therapy for Spinal Metastases. Steverink JG, Willems SM, Philippens MEP, Kasperts N, Eppinga WSC, Versteeg AL, van der Velden JM, Faruqi S, Sahgal A, Verlaan JJ. *Int J Radiat Oncol Biol Phys*. 2018 Apr 1;100(5):1254-1258.
103. Beam characterisation of the 1.5 T MRI-linac. Woodings SJ, Bluemink JJ, de Vries JHW, Niatetski Y, van Veelen B, Schillings J, Kok JGM, Wolthaus JWH, Hackett SL, van Asselen B, van Zijp HM, Pencea S, Roberts DA, Lagendijk JJW, Raaymakers BW. *Phys Med Biol*. 2018 Apr 19;63(8).
104. Spiraling contaminant electrons increase doses to surfaces outside the photon beam of an MRI-linac with a perpendicular magnetic field. Hackett SL, van Asselen B, Wolthaus JWH, Bluemink JJ, Ishakoglu K, Kok J, Lagendijk JJW, Raaymakers BW. *Phys Med Biol*. 2018 May 1;63(9).
105. Long-term survival after relapsed NUT carcinoma of the larynx. Vorstenbosch LJM, Mavinkurve-Groothuis AMC, van den Broek G, Flucke U, Janssens GO. *Pediatr Blood Cancer*. 2018 May;65(5).
106. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study. Goense L, Visser E, Haj Mohammad N, Mook S, Verhoeven RHA, Meijer GJ, van Rossum PSN, Ruurda JP, van Hillegersberg R. *Eur J Surg Oncol*. 2018 May;44(5):620-625.
107. Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol. Gooskens SL, Graf N, Furtwängler R, Spreafico F, Bergeron C, Ramírez-Villar GL, Godzinski J, Rübe C, Janssens GO, Vujanic GM, Leuschner I, Coulomb-L'Hermine A, Smets AM, de Camargo B, Stoneham S, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM; International Society of Paediatric Oncology-Renal Tumour Study Group (SIOP-RTSG). *Nat Rev Urol*. 2018 May;15(5):309-319.
108. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014. Jeene PM, de Vries KC, van Nes JGH, Kwakman JJM, Wester

- G, Rozema T, Braam PM, Zindler JD, Koper P, Nuyttens JJ, Vos-Westerman HA, Schmeets I, Niël CGHJ, Hutschemaekers S, van der Linden YM, Verhoeff JJC, Stalpers LJA. *Acta Oncol.* 2018 May;57(5):637-643.
109. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. Wolff HB, Alberts L, Kastelijan EA, Lissenberg-Witte BI, Twisk JW, Lagerwaard FJ, Senan S, El Sharouni SY, Schramel FMNH, Coupé VMH. *J Thorac Oncol.* 2018 May;13(5):689-698.
110. Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy. Maspero M, Seevinck PR, Willems NJW, Sikkes GG, de Kogel GJ, de Boer HCJ, van der Voort van Zyp JRN, van den Berg CAT. *Radiat Oncol.* 2018 Jun 5;13(1).
111. Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI. Van den Begin R, Kleijnen JP, Engels B, Philippens M, van Asselen B, Raaymakers B, Reerink O, De Ridder M, Intven M. *Acta Oncol.* 2018 Jun;57(6):723-727.
112. The accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments. van Stam MA, Aaronson NK, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, Horenblas S, Bosch JLHR. *Ned Tijdschr Geneeskd.* 2018 Jun 7;162.
113. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazon R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K; EMBRACE Collaborative Group. *Radiother Oncol.* 2018 Jun;127(3):431-439.
114. A formalism for reference dosimetry in photon beams in the presence of a magnetic field. van Asselen B, Woodings SJ, Hackett SL, van Soest TL, Kok JGM, Raaymakers BW, Wolthaus JWH. *Phys Med Biol.* 2018 Jun 11;63(12).
115. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K. *Radiother Oncol.* 2018 Jun;127(3):423-430.
116. Patient perspectives on repeated MRI and PET/CT examinations during neoadjuvant treatment of esophageal cancer. Goense L, Borggreve AS, Heethuis SE, van Lier AL, van Hillegersberg R, Mook S, Meijer GJ, van Rossum PS, Ruurda JP. *Br J Radiol.* 2018 Jun;91(1086).
117. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Goense L, van Rossum PSN, Xi M, Maru DM, Carter BW, Meijer GJ, Ho L, van Hillegersberg R, Hofstetter WL, Lin SH. *Ann Surg Oncol.* 2018 Jun;25(6):1598-1607.
118. Automatic quantification of calcifications in the coronary arteries and thoracic aorta on radiotherapy planning CT scans of Western and Asian breast cancer patients. Gernaat SAM, van Velzen SGM, Koh V, Emaus MJ, Išgum I, Lessmann N, Moes S, Jacobson A, Tan PW, Grobbee DE, van den Bongard DHJ, Tang JI, Verkooijen HM. *Radiother Oncol.* 2018 Jun;127(3):487-492.
119. EMBRACE Collaborative Group. Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study. Smet S, Pötter R, Haie-Meder C, Lindegaard JC, Schulz-Juergenliemk I, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van Limbergen E, Tanderup K, Kirchheiner K; Radiother Oncol. 2018 Jun;127(3):440-448.
120. Quantification of variations in intra-fraction motion of esophageal tumors over the course of neoadjuvant chemoradiotherapy based on cine-MRI. Heethuis SE, Borggreve AS, Goense L, van Rossum PSN, Mook S, van Hillegersberg R, Ruurda JP, Meijer GJ, Lagendijk JJW, van Lier ALHMW. *Phys Med Biol.* 2018 Jul 19;63(14).
121. Intra- and inter-fraction uncertainties during IGRT for Wilms' tumor. Guerreiro F, Seravalli E, Janssens GO, van de Ven CP, van den Heuvel-Eibrink MM, Raaymakers BW. *Acta Oncol.* 2018 Jul;57(7):941-949.
122. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer. Hoendervangers S, Couwenberg AM, Intven MPW, van Grevenstein WMU, Verkooijen HM. *Eur J Surg Oncol.* 2018 Jul;44(7):1013-1017.
123. Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study. Teepen JC, Kok JL, van Leeuwen FE, Tissing WJE, Dolsma WV, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van den Berg MH, van der Heiden-van der Loo M, Hauptmann M, Jongmans MC, Overbeek LI, van de Vijver MJ, Kremer LCM, Ronckers CM, Aleman BMP, Caron HN, Daniels LA, Grootenhuis MA, Haasbeek CJ, den Hartogh JG, Hauptmann M, Hollema N, Janssens GO, Jaspers MWM, Maduro JH, Neggers SJ, Oldenburger F, Overbeek LI, Postma A, de Ridder-Sluiter JG, van Rij CM, Tersteeg RJ, Versluys AB, Zsifros J. *J Natl Cancer Inst* 2018 Jul;110:758-67.

124. Error analysis of helmholtz-based MR-electrical properties tomography. Mandija S, Sbrizzi A, Katscher U, Luijten PR, van den Berg CAT. *Magn Reson Med*. 2018 Jul;80(1):90-100.
125. Modified dixon-based renal dynamic contrast-enhanced MRI facilitates automated registration and perfusion analysis. de Boer A, Leiner T, Vink EE, Blankestijn PJ, van den Berg CAT. *Magn Reson Med*. 2018 Jul;80(1):66-76.
126. The risk of cardiovascular disease following breast cancer by Framingham risk score. Gernaat SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, van der Pol CC, Bijlsma RM, Grobbee DE, Verkooijen HM, Peeters PH. *Breast Cancer Res Treat*. 2018 Jul;170(1):119-127.
127. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD. *Clin Transl Radiat Oncol*. 2018 Aug 24;13:19-23.
128. Prospective Respiration Detection in Magnetic Resonance Imaging by a Non-Interfering Noise Navigator. Navest RJM, Andreychenko A, Lagendijk JJW, van den Berg CAT. *IEEE Trans Med Imaging*. 2018 Aug;37(8):1751-1760.
129. Verification of HE-based CTV in laryngeal and hypopharyngeal cancer using pan-cytokeratin. Ligtenberg H, Willems SM, Ruiters LN, Jager EA, Terhaard CHJ, Raaijmakers CPJ, Philippens MEP. *Clin Transl Radiat Oncol*. 2018 Jul 11;12:21-27.
130. The interobserver agreement in the detection of recurrent HNSCC using MRI including diffusion weighted MRI. Peltenburg B, Driessen JP, Philippens MEP, Pameijer FA, Castelijns J, Dankbaar JW, Dorgelo B, Lange CAH, Meijer FJA, Palm WM, Roosendaal SD, Steens SCA, Verbist BM, Stegeman I, Janssen LM, de Bree R, Terhaard CHJ. *Eur J Radiol*. 2018 Aug;105:134-140.
131. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers SJCMM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, van Rij C, Tersteeg RJHA, Hauptmann M; DCOG-LATER Study Group, Kremer LCM, Ronckers CM. *Neuro Oncol*. 2018 Aug 7.
132. Anatomically plausible models and quality assurance criteria for online mono- and multi-modal medical image registration. Zachiu C, de Senneville BD, Moonen CTW, Raaymakers BW, Ries M. *Phys Med Biol*. 2018 Aug 1;63(15).
133. Role of adjuvant chemoradiotherapy after endoscopic treatment of early-stage esophageal cancer: a systematic review. Goense L, Meziani J, Borggreve AS, van Rossum PS, Meijer GJ, Ruurda JP, van Hillegersberg R, Weusten BL. *Minerva Chir*. 2018 Aug;73(4):428-436.
134. Characterization of imaging latency for real-time MRI-guided radiotherapy. Borman PTS, Tijssen RHN, Bos C, Moonen CTW, Raaymakers BW, Glitzner M. *Phys Med Biol*. 2018 Aug 6;63(15).
135. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry. Dávila Fajardo R, Oldenburger E, Rube C, López-Yurda M, Pritchard-Jones K, Bergeron C, Graf N, van Grotel M, van Tinteren H, Saunders D, van den Heuvel-Eibrink MM, Janssens GO, Oldenburger F. *Pediatr Blood Cancer*. 2018 Aug;65(8).
136. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM. *J Clin Oncol*. 2018 Aug 10;36(23):2366-2377.
137. Utility Scores and Preferences for Surgical and Organ-Sparing Approaches for Treatment of Intermediate and High-Risk Rectal Cancer. Couwenberg AM, Intven MPW, Burbach JPM, Emaus MJ, van Grevenstein WMU, Verkooijen HM. *Dis Colon Rectum*. 2018 Aug;61(8):911-919.
138. SIOPE-Brain Tumor Group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Ajithkumar TV, Horan G, Padovani L, Thorp N, Timmermann B, Alapetite C, Gandola L, Ramos M, van Beek K, Christiaens M, Lassen-Ramshad Y, Magelssen H, Nilsson K, Saran F, Rombi B, Kortmann RD, Janssens GO. *Radiotherapy & Oncology*, 2018 Aug;128:192-7.

139. Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Rutkowski S, Modena P, Williamson D, Kerl K, Nysom K, Pizer B, Bartels U, Puget S, Doz F, Michalski A, von Hoff K, Chevignard M, Avula S, Murray MJ, Schönberger S, Czech T, Schouten-van Meeteren AYN, Kordes U, Kramm CM, van Vuurden DG, Hulleman E, Janssens GO, Solanki GA, van Veelen MC, Thomale U, Schuhmann MU, Jones C, Giangaspero F, Figarella-Branger D, Pietsch T, Clifford SC, Pfister SM, Van Gool SW. *Lancet Oncol.* 2018 Aug;19(8).
140. Triggered radiosensitizer delivery using thermosensitive liposomes and hyperthermia improves efficacy of radiotherapy: An in vitro proof of concept study. Besse HC, Bos C, Zandvliet MMJM, van der Wurff-Jacobs K, Moonen CTW, Deckers R. *PLoS One.* 2018 Sep 18;13(9).
141. Design of a forward view antenna for prostate imaging at 7 T. Steensma BR, Voogt I, van der Werf AJ, van den Berg CAT, Luijten PR, Klomp DWJ, Raaijmakers AJE. *NMR Biomed.* 2018 Sep;31(9).
142. Dosimetric comparison of five different techniques for craniospinal irradiation across 15 European centers: analysis on behalf of the SIOP-E-BTG (radiotherapy working group). Seravalli E, Bosman M, Lassen-Ramshad Y, Vestergaard A, Oldenburger F, Visser J, Koutsouveli E, Paraskevopoulou C, Horan G, Ajithkumar T, Timmermann B, Fuentes CS, Whitfield G, Marchant T, Padovani L, Garnier E, Gandola L, Meroni S, Hoeben BAW, Kusters M, Alapetite C, Losa S, Goudjil F, Magelssen H, Evensen ME, Saran F, Smyth G, Rombi B, Righetto R, Kortmann RD, Janssens GO. *Acta Oncol.* 2018 Sep;57(9):1240-1249.
143. Dose evaluation of fast synthetic-CT generation using a generative adversarial network for general pelvis MR-only radiotherapy. Maspero M, Savenije MHF, Dinkla AM, Seevinck PR, Intven MPW, Jurgensliemk-Schulz IM, Kerkmeijer LGW, van den Berg CAT. *Phys Med Biol.* 2018 Sep 10;63(18).
144. Single dose partial breast irradiation using an MRI linear accelerator in the supine and prone treatment position. Charaghvandi KR, Van't Westeinde T, Yoo S, Houweling AC, Rodrigues A, Verkooijen HM, Philippens MEP, van Asselen B, Horton JK, van den Bongard HJGD. *Clin Transl Radiat Oncol.* 2018 Sep 5;14:1-7.
145. Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation. van den Bosch S, Vogel WV, Raaijmakers CP, Dijkema T, Terhaard CHJ, Al-Mamgani A, Kaanders JHAM. *Radiother Oncol.* 2018 Sep;128(3):472-478.
146. Phase matched RF pulse design for imaging a reduced field of excitation with a fast TSE acquisition. Mooiweer R, Sbrizzi A, Raaijmakers AJE, van den Berg CAT, Luijten PR, Hoogduin H. *Magn Reson Imaging.* 2018 Sep;51:128-136.
147. 3-D Contrast Source Inversion-Electrical Properties Tomography. Leijssen RL, Brink WM, van den Berg CAT, Webb AG, Remis RF. *IEEE Trans Med Imaging.* 2018 Sep;37(9):2080-2089.
148. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged \geq 70 Years With Locally Advanced Rectal Cancer. Jacobs L, van der Vlies E, Ten Bokkel Huinink D, Bloemendal H, Intven M, Smits AB, Weusten BLAM, Siersema PD, van Lelyveld N, Los M. *Clin Colorectal Cancer.* 2018 Sep;17(3):179-186.
149. Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis. Couwenberg AM, Burbach JPM, van Grevenstein WMU, Smits AB, Consten ECJ, Schiphorst AHW, Wijffels NAT, Heikens JT, Intven MPW, Verkooijen HM. *Clin Colorectal Cancer.* 2018 Sep;17(3).
150. Imaging predictors of treatment outcomes in rectal cancer: An overview. Mahadevan LS, Zhong J, Venkatesulu B, Kaur H, Bhide S, Minsky B, Chu W, Intven M, van der Heide UA, van Triest B, Krishnan S, Hall WA. *Crit Rev Oncol Hematol.* 2018 Sep;129:153-162.
151. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPW, van Santvoort HC, Molenaar IQ. *Eur J Radiol.* 2018 Sep;106:128-136.
152. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients? Janssens GO, Kramm CM, von Bueren AO. *J Neurooncol.* 2018 Sep;139(2):501.
153. A novel digital workflow to manufacture personalized three-dimensional-printed hollow surgical obturators after maxillectomy. Kortjes J, Dehnad H, Kotte ANT, Fennis WMM, Rosenberg AJWP. *Int J Oral Maxillofac Surg.* 2018 Sep;47(9):1214-1218.
154. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer. Heethuis SE, Goense L, van Rossum PSN, Borggreve AS, Mook S, Voncken FEM, Bartels-Rutten A, Aleman BMP, van Hillegersberg R, Ruurda JP, Meijer GJ, Lagendijk JJW, van Lier ALHMW. *Acta Oncol.* 2018 Sep;57(9):1201-1208.
155. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Wortman BG, Creutzberg CL, Putter H, Jurgensliemk-Schulz IM, Jobsen JJ,

- Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group. *Br J Cancer*. 2018 Oct;119(9):1067-1074.
156. Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: A nationwide study. Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Aleman BMP, Nijkamp J, Meijer GJ, Lips IM; Dutch National Platform for Radiotherapy of Gastrointestinal Tumours (LPRGE) group. *Clin Transl Radiat Oncol*. 2018 Oct 26;14:33-39.
157. Declining free thyroxine levels over time in irradiated childhood brain tumor survivors. van Iersel L, Clement SC, Schouten-van Meeteren AYN, Boot A, Claahsen-van der Grinten HL, Granzen B, Han KS, Janssens GO, Michiels EM, van Trotsenburg P, Vandertop P, van Vuurden DG, Caron H, Kremer LC, van Santen HM. *Endocr Connect*. 2018 Oct 1.
158. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. Borggreve AS, Mook S, Verheij M, Mul VEM, Bergman JJ, Bartels-Rutten A, Ter Beek LC, Beets-Tan RGH, Bennink RJ, van Berge Henegouwen MI, Brosens LAA, Defize IL, van Dieren JM, Dijkstra H, van Hilleegersberg R, Hulshof MC, van Laarhoven HWM, Lam MGEH, van Lier ALHMW, Muijs CT, Nagengast WB, Nederveen AJ, Noordzij W, Plukker JTM, van Rossum PSN, Ruurda JP, van Sandick JW, Weusten BLAM, Voncken FEM, Yakar D, Meijer GJ; PRIDE study group. *BMC Cancer*. 2018 Oct 20;18(1):1006.
159. MR-Only Brain Radiation Therapy: Dosimetric Evaluation of Synthetic CTs Generated by a Dilated Convolutional Neural Network. Dinkla AM, Wolterink JM, Maspero M, Savenije MHF, Verhoeff JJC, Seravalli E, Išgum I, Seevinck PR, van den Berg CAT. *Int J Radiat Oncol Biol Phys*. 2018 Nov 15;102(4):801-812.
160. Nuts and bolts of 4D-MRI for radiotherapy. Iuijten B, Paulson ES, Tijssen RHN. *Phys Med Biol*. 2018 Oct 23;63(21).
161. Magnetic Resonance Imaging only Workflow for Radiotherapy Simulation and Planning in Prostate Cancer. Kerkmeijer LGW, Maspero M, Meijer GJ, van der Voort van Zyp JRN, de Boer HCJ, van den Berg CAT. *Clin Oncol (R Coll Radiol)*. 2018 Nov;30(11):692-701.
162. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Heerkens HD, van Vulpen M, Erickson B, Reerink O, Intven MP, van den Berg CA, Molenaar IQ, Vleggaar FP, Meijer GJ. *Br J Radiol*. 2018 Nov;91(1091).
163. A novel concurrent TMS-fMRI method to reveal propagation patterns of prefrontal magnetic brain stimulation. Vink JJT, Mandija S, Petrov PI, van den Berg CAT, Sommer IEC, Neggers SFW. *Hum Brain Mapp*. 2018 Nov;39(11):4580-4592.
164. Development and Testing of a Magnetic Resonance (MR) Conditional Afterloader for Source Tracking in Magnetic Resonance Imaging-Guided High-Dose-Rate (HDR) Brachytherapy. Beld E, Seevinck PR, Schuurman J, Viergever MA, Lagendijk JJW, Moerland MA. *Int J Radiat Oncol Biol Phys*. 2018 Nov 15;102(4):960-968.
165. Volumetric wireless coil based on periodically coupled split-loop resonators for clinical wrist imaging. Shchelokova AV, van den Berg CAT, Dobrykh DA, Glybovski SB, Zubkov MA, Brui EA, Dmitriev DS, Kozachenko AV, Efimtcev AY, Sokolov AV, Fokin VA, Melchakova IV, Belov PA. *Magn Reson Med*. 2018 Oct;80(4):1726-1737.
166. Evaluation of effectiveness of palliative radiotherapy for bone metastases: a prospective cohort study. van der Velden JM, van der Linden YM, Versteeg AL, Verlaan JJ, Sophie Gerlich A, Pielkenrood BJ, Kasperts N, Verkooijen HM. *J Radiat Oncol*. 2018;7(4):325-333.
167. Stereotactic Radiotherapy Followed by Surgical Stabilization Within 24 h for Unstable Spinal Metastases; A Stage I/IIa Study According to the IDEAL Framework. Versteeg AL, van der Velden JM, Hes J, Eppinga W, Kasperts N, Verkooijen HM, Oner FC, Seravalli E, Verlaan JJ. *Front Oncol*. 2018 Dec 20;8:626.
168. Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5T MR-linac. Winkel D, Kroon PS, Werensteijn-Honingh AM, Bol GH, Raaymakers BW, Jürgenliemk-Schulz IM. *Acta Oncol*. 2018 Dec;57(12):1705-1712.
169. Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. van Son M, Peters M, Moerland M, Kerkmeijer L, Lagendijk J, van der Voort van Zyp J. *Cancers (Basel)*. 2018 Dec 3;10(12).
170. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Kroese TE, Goense L, van Hilleegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN. *Dis Esophagus*. 2018 Dec 1;31(12).

171. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. Maenhout M, Peters M, Moerland MA, Meijer RP, van den Bosch MAAJ, Frank SJ, Nguyen PL, van Vulpen M, van der Voort van Zyp JRN. *Radiother Oncol.* 2018 Dec;129(3):554-560.
172. Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients. Peltenburg B, de Keizer B, Dankbaar JW, de Boer M, Willems SM, Philippens MEP, Terhaard CHJ, de Bree R. *Acta Oncol.* 2018 Dec;57(12):1687-1692.
173. Chapter in book: Perez & Brady's Principles & Practice of Radiation Oncology, Chapter 46, Chris H.J. Terhaard. *Salivary Glands.* 7th revised edition 2018.
174. Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. Jamal DN, Pötter R, Haie-Meder C, Lindegaard JC, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Tanderup K, Kirchheiner K, and the EMBRACE collaborative group. *Radiotherapy and Oncology* 2018: 127 449-455.
175. Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy. Serban M, Kirisits C, Pötter R, De Leeuw A, Nkiwane K, Dumas I, Nesvacil N et al. *Radiotherapy and Oncology* 129 (2018) 567-574.
176. MRI-based, wireless determination of the transfer function of a linear implant: Introduction of the transfer matrix. Tokaya JP, Raaijmakers AJE, Luijten PR, van den Berg CAT. *Magn Reson Med.* 2018 Dec;80(6):2771-2784.

2017

177. Real-time auto-adaptive margin generation for MLC-tracked radiotherapy. Glitzner M, Fast MF, de Senneville BD, Nill S, Oelfke U, Lagendijk JJ, Raaymakers BW, Crijs SP. *Phys Med Biol.* 2017 Jan 7;62(1).
178. Thermal noise variance of a receive radiofrequency coil as a respiratory motion sensor. Andreychenko A, Raaijmakers AJ, Sbrizzi A, Crijs SP, Lagendijk JJ, Luijten PR, van den Berg CA. *Magn Reson Med.* 2017 Jan;77(1):221-228.
179. The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA): objectives, design, and baseline results. Young-Afat DA, van Gils CH, van den Bongard HJGD, Verkooijen H M; UMBRELLA Study Group. *Breast Cancer Res Treat* 2017;164:445-450.
180. Optimal control design of turbo spin-echo sequences with applications to parallel-transmit systems. Sbrizzi A, Hoogduin H, Hajnal JV, van den Berg CA, Luijten PR, Malik SJ. *Magn Reson Med.* 2017 Jan;77(1):361-373.
181. MRI-geleide brachytherapie bij prostaatkankerrecidief. [MRI-guided brachytherapy in prostate cancer]. Peters M, Moerland MA, Noteboom JL, Eppinga WS, Lagendijk JJ, van der Voort van Zyp JRN. *Ned Tijdschr Geneeskd.* 2017;161:D1708.
182. The peri-esophageal connective tissue layers and related compartments: visualization by histology and magnetic resonance imaging. Weijs TJ, Goense L, van Rossum PS, Meijer GJ, van Lier AL, Wessels FJ, Braat MN, Lips IM, Ruurda JP, Cuesta MA, van Hillegersberg R, Bleys RL. *J Anat.* 2017 Feb;230(2):262-271.
183. B1-based SAR reconstruction using contrast source inversion-electric properties tomography (CSI-EPT). Balidemaj E, van den Berg CA, van Lier AL, Nederveen AJ, Stalpers LJ, Crezee H, Remis RF. *Med Biol Eng Comput.* 2017 Feb;55(2):225-233.
184. Quantification of confounding factors in MRI-based dose calculations as applied to prostate IMRT. Maspero M, Seevinck PR, Schubert G, Hoesl MA, van Asselen B, Viergever MA, Lagendijk JJ, Meijer GJ, van den Berg CA. *Phys Med Biol.* 2017 Feb 7;62(3):948-965.
185. Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program. Cnossen IC, van Uden-Kraan CF, Witte BI, Aalders YJ, de Goede CJ, de Bree R, Doornaert P, Rietveld DH, Buter J, Langendijk JA, Leemans CR, Verdonck-de Leeuw IM. *Eur Arch Otorhinolaryngol.* 2017 Feb;274(2):1129-1138.
186. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Józwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME. *BMC Cancer.* 2017 Feb 7;17(1):112.

187. B1-based SAR reconstruction using contrast source inversion-electric properties tomography (CSI-EPT). Balidemaj E, van den Berg CA, van Lier AL, Nederveen AJ, Stalpers LJ, Crezee H, Remis RF. *Med Biol Eng Comput.* 2017 Feb;55(2):225-233.
188. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. van den Bosch S, Dijkema T, Kunze-Busch MC, Terhaard CH, Raaijmakers CP, Doornaert PA, Hoebbers FJ, Vergeer MR, Kreike B, Wijers OB, Oyen WJ, Kaanders JH. *BMC Cancer.* 2017 Mar 21;17(1):208.
189. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol. Charaghvandi RK, van Asselen B, Philippens ME, Verkooijen HM, van Gils CH, van Diest PJ, Pijnappel RM, Hobbelenk MG, Witkamp AJ, van Dalen T, van der Wall E, van Heijst TC, Koelemij R, van Vulpen M, van den Bongard HJ. *BMC Cancer.* 2017 Mar 9;17(1).
190. Probabilistic treatment planning for pancreatic cancer treatment: prospective incorporation of respiratory motion shows only limited dosimetric benefit. Lens E, Kotte AN, Patel A, HD, Bal M, van Tienhoven G, Bel A, van der Horst A, Meijer GJ. *Acta Oncol.* 2017 Mar;56(3):398-404.
191. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Heerkens HD, Hall WA, Li XA, Knechtges P, Dalah E, Paulson ES, van den Berg CA, Meijer GJ, Koay EJ, Crane CH, Aitken K, van Vulpen M, Erickson BA. *Pract Radiat Oncol.* 2017 Mar - Apr;7(2):126-13.
192. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM. *Eur J Cancer.* 2017 Mar;73:38-47.
193. Patient Preferences for Minimally Invasive and Open Locoregional Treatment for Early-Stage Breast Cancer. Knuttel FM, van den Bosch MA, Young-Afat DA, Emaus MJ, van den Bongard DH, Witkamp AJ, Verkooijen HM. *Value Health.* 2017 Mar;20(3):474-480.
194. Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for ¹²⁵I prostate brachytherapy. Peters M, Smit Duijzentkunst DA, Westendorp H, van de Pol SMG, Kattevilder R, Schellekens A, van der Voort van Zyp JRN, Moerland MA, van Vulpen M, Hoekstra CJ. *Brachytherapy.* 2017 Mar - Apr;16(2):282-290.
195. Postoperative single-dose interstitial high-dose-rate brachytherapy in therapy-resistant keloids. Hafkamp CJH, Lapid O, Dávila Fajardo R, van de Kar AL, Koedooder C, Stalpers LJ, Pieters BR. *Brachytherapy.* 2017 Mar - Apr;16(2):415-420.
196. Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution. Tseng CL, Eppinga W, Charest-Morin R, Soliman H, Myrehaug S, Maralani PJ, Campbell M, Lee YK, Fisher C, Fehlings MG, Chang EL, Lo SS, Sahgal A. *Global Spine J.* 2017 Apr;7(2):179-197.
197. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C. *Front Oncol.* 2017 Apr 3;7:59.
198. Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. Maenhout M, van Vulpen M, Moerland M, Peters M, Meijer R, van den Bosch M, Nguyen P, Frank S, van der Voort van Zyp J. *J Contemp Brachytherapy.* 2017 Apr;9(2):161-166.
199. Indicators for Enteral Nutrition Use and Prophylactic Percutaneous Endoscopic Gastrostomy Placement in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy. van der Linden NC, Kok A, Leermakers-Vermeer MJ, de Roos NM, de Bree R, van Cruijssen H, Terhaard CH. *Nutr Clin Pract.* 2017 Apr;32(2):225-232.
200. Validating subject-specific RF and thermal simulations in the calf muscle using MR-based temperature measurements. Simonis FF, Raaijmakers AJ, Lagendijk JJ, van den Berg CA. *Magn Reson Med.* 2017 Apr;77(4):1691-1700.
201. Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI. Ligtenberg H, Jager EA, Caldas-Magalhaes J, Schakel T, Pameijer FA, Kasperts N, Willems SM, Terhaard CH, Raaijmakers CP, Philippens ME. *Radiother Oncol.* 2017 Apr;123(1):63-70.
202. Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Veldhuijzen van Zanten SE, Baugh J, Chaney B, De Jongh D, Sanchez Aliaga E, Barkhof F, Noltes J, De Wolf R, Van Dijk J, Cannarozzo A, Damen-Korbijn CM, Lieverst JA,

- Colditz N, Hoffmann M, Warmuth-Metz M, Bison B, Jones DT, Sturm D, Gielen GH, Jones C, Hulleman E, Calmon R, Castel D, Varlet P, Giraud G, Slavic I, Van Gool S, Jacobs S, Jadrijevic-Cvrlje F, Sumerauer D, Nysom K, Pentikainen V, Kivivuori SM, Leblond P, Entz-Werle N, von Bueren AO, Kattamis A, Hargrave DR, Hauser P, Garami M, Thorarinsdottir HK, Pears J, Gandola L, Rutkauskiene G, Janssens GO, Torsvik IK, Perek-Polnik M, Gil-da-Costa MJ, Zheludkova O, Shats L, Deak L, Kitanovski L, Cruz O, Morales La Madrid A, Holm S, Gerber N, Kebudi R, Grundy R, Lopez-Aguilar E, Zapata-Tarres M, Emmerik J, Hayden T, Bailey S, Biassoni V, Massimino M, Grill J, Vandertop WP, Kaspers GJ, Fouladi M, Kramm CM, van Vuurden DG; members of the SIOPE DIPG Network. *J Neurooncol.* 2017 Apr;132(2):255-266.
203. The feasibility of semi-automatically generated red bone marrow segmentations based on MR-only for patients with gynecologic cancer. Andreychenko A, Kroon PS, Maspero M, Jürgenliemk-Schulz I, De Leeuw AA, Lam MG, Lagendijk JJ, van den Berg CA. *Radiother Oncol.* 2017 Apr;123(1):164-168.
204. Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Li WS, van der Velden JM, Ganesh V, Vuong S, Raman S, Popovic M, Lam H, Wong KH, Ngan RK, Burbach JPM, DeAngelis C, XXXX RM, Chow E. *Ann Palliat Med.* 2017 Apr;6(2):104-117.
205. Cone-beam CT-based adaptive planning improves permanent prostate brachytherapy dosimetry: An analysis of 1266 patients. Westendorp H, Hoekstra CJ, Immerzeel JJ, van de Pol SM, Niël CG, Kattevilder RA, Nuver TT, Minken AW, Moerland MA. *Med Phys.* 2017 Apr;44(4):1257-1267.
206. Patterns of care survey: Radiotherapy for women with locally advanced cervical cancer. de Boer P, Jürgenliemk-Schulz IM, Westerveld H, de Leeuw AAC, Dávila-Fajardo R, Rasch CRN, Pieters BR, Stalpers LJA. *Radiother Oncol.* 2017 May;123(2):306-311.
207. A phantom study: Should ¹²⁴I-mIBG PET/CT replace ¹²³I-mIBG SPECT/CT? Beijst C, de Keizer B, Lam MGEH, Janssens GO, Tytgat GAM, de Jong HWAM. *Med Phys.* 2017 May;44(5):1624-1631.
208. A novel adaptive needle insertion sequencing for robotic, single needle MR-guided high-dose-rate prostate brachytherapy. Borot de Battisti M, Denis de Senneville B, Hautvast G, Binnekamp D, Lagendijk JJW, Maenhout M, Moerland MA. *Phys Med Biol.* 2017 May 21;62(10):4031-4045.
209. Dosimetric impact of contouring and image registration variability on dynamic (125)I prostate brachytherapy. Westendorp H, Surmann K, van de Pol SMG, Hoekstra CJ, Kattevilder RAJ, Nuver TT, Moerland MA, Slump CH, Minken AW. *Brachytherapy.* 2017 May - Jun;16(3):572-578.
210. Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Lamba N, Muskens IS, DiRisio AC, Meijer L, Briceno V, Edrees H, Aslam B, Minhas S, Verhoeff JJC, Kleynen CE, Smith TR, Mekary RA, Broekman ML. *Radiat Oncol.* 2017 Jun 24;12(1):106.
211. How much detail is needed in modeling a transcranial magnetic stimulation figure-8 coil: Measurements and brain simulations. Petrov PI, Mandija S, Sommer IEC, van den Berg CAT, Neggers SFW. *PLoS One.* 2017 Jun 22;12(6).
212. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival. Goense L, van der Sluis PC, van Rossum PSN, van der Horst S, Meijer GJ, Haj Mohammad N, van Vulpen M, Mook S, Ruurda JP, van Hillegersberg R. *J Surg Oncol.* 2017 Jun;115(7):812-820.
213. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. van der Horst S, Weijs TJ, Ruurda JP, Haj Mohammad N, Mook S, Brosens LAA, van Hillegersberg R. *J Thorac Dis.* 2017 Jul;9(Suppl 8):S834-S842.
214. Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase I HERBERT Study. Rijkmans EC, Cats A, Nout RA, van den Bongard DHJG, Ketelaars M, Buijsen J, Rozema T, Franssen JH, Velema LA, van Triest B, Marijnen CAM. *Int J Radiat Oncol Biol Phys.* 2017 Jul 15;98(4):908-917.
215. Combining a reduced field of excitation with SENSE-based parallel imaging for maximum imaging efficiency. Mooiweer R, Sbrizzi A, Raaijmakers AJE, van den Berg CAT, Luijten PR, Hoogduin H. *Magn Reson Med.* 2017 Jul;78(1):88-96.
216. Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients. Middelburg JG, Mast ME, de Kroon M, Jobsen JJ, Rozema T, Maas H, Baartman EA, Geijsen D, van der Leest AH, van den Bongard DJ, van Loon J, Budiharto T, Coebergh JW, Aarts MJ, Struikmans H; LPRO (Dutch National Organization for Radiotherapy in the Elderly). *Int J Radiat Oncol Biol Phys.* 2017 Jul 15;98(4):843-849.

217. Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy. Ma J, Moerland MA, Venkatesan AM, Bathala TK, Kudchadker RJ, Brock KK, Frank SJ. *Brachytherapy*. 2017 Jul - Aug;16(4):743-753.
218. Supine MRI for regional breast radiotherapy: imaging axillary lymph nodes before and after sentinel-node biopsy. van Heijst TCF, Eschbach-Zandbergen D, Hoekstra N, van Asselen B, Lagendijk JJW, Verkooijen HM, Pijnappel RM, de Waard SN, Witkamp AJ, van Dalen T, van den Bongard HJGD, Philippens MEP. *Phys Med Biol*. 2017 Aug 1;62(16):6746-6761.
219. Electric properties tomography: Biochemical, physical and technical background, evaluation and clinical applications. Katscher U, van den Berg CAT. *NMR Biomed*. 2017 Aug;30(8).
220. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ, de Bree R, Pothen AJ. *Oral Oncol*. 2017 Aug;71:26-33.
221. ABVD or BEACOPP_{baseline} along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerd O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte Eur J Cancer. 2017 Aug;81:45-55.
222. Technical Note: Diffusion-weighted MRI with minimal distortion in head-and-neck radiotherapy using a turbo spin echo acquisition method. Schakel T, Hoogduin JM, Terhaard CHJ, Philippens MEP. *Med Phys*. 2017 Aug;44(8):4188-4193.
223. Variation in head and neck cancer care in the Netherlands: A retrospective cohort evaluation of incidence, treatment and outcome. de Ridder M, Balm AJM, Baatenburg de Jong RJ, Terhaard CHJ, Takes RP, Slingerland M, Dik E, Sedee RJE, de Visscher JGAM, Bouman H, Willems SM, Wouters MW, Smeele LE, van Dijk BAC; Dutch Head and Neck Research Group. *Eur J Surg Oncol*. 2017 Aug;43(8):1494-1502.
224. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. Kanthabalan A, Peters M, Van Vulpen M, McCartan N, Hindley RG, Emará A, Moore CM, Arya M, Emberton M, Ahmed HU. *BJU Int*. 2017 Aug;120(2):246-256.
225. Prospective Evaluation of the Relationship between Mechanical Stability and Response to Palliative Radiotherapy for Symptomatic Spinal Metastases. van der Velden JM, Versteeg AL, Verkooijen HM, Fisher CG, Chow E, Oner FC, van Vulpen M, Weir L, Verlaan JJ. *Oncologist*. 2017 Aug;22(8):972-978.
226. Towards fast online intrafraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac. Kontaxis C, Bol GH, Stemkens B, Glitzner M, Prins FM, Kerkmeijer LGW, Lagendijk JJW, Raaymakers BW. *Phys Med Biol*. 2017 Aug 21;62(18):7233-7248.
227. Effect of intra-fraction motion on the accumulated dose for free-breathing MR-guided stereotactic body radiation therapy of renal-cell carcinoma. Stemkens B, Glitzner M, Kontaxis C, de Senneville BD, Prins FM, Crijns SPM, Kerkmeijer LGW, Lagendijk JJW, van den Berg CAT, Tijssen RHN. *Phys Med Biol*. 2017 Sep 1;62(18):7407-7424.
228. Evaluation of an automatic MR-based gold fiducial marker localisation method for MR-only prostate radiotherapy. Maspero M, van den Berg CAT, Zijlstra F, Sikkes GG, de Boer HCJ, Meijer GJ, Kerkmeijer LGW, Viergever MA, Lagendijk JJW, Seevinck PR. *Phys Med Biol*. 2017 Oct 3;62(20):7981-8002.
229. The effects of exercise on the quality of life of patients with breast cancer (the UMBRELLA Fit study): study protocol for a randomized controlled trial. Gal R, Monnikhof EM, Groenwold RHH, van Gils CH, van den Bongard DHJG, Peeters PHM, Verkooijen HM, May AM. *Trials*. 2017 Oct 27;18(1):504.
230. Ischemic stroke after radiation therapy for pituitary adenomas: a systematic review. van Westrhenen A, Muskens IS, Verhoeff JJC, Smith TRS, Broekman MLD. *J Neurooncol*. 2017 Oct;135(1):1-11.
231. Detection of cartilage invasion in laryngeal carcinoma with dynamic contrast-enhanced CT. Dankbaar JW, Oosterbroek J, Jager EA, de Jong HW, Raaijmakers CP, Willems SM, Terhaard CH, Philippens ME, Pameijer FA. *Laryngoscope Invest Otolaryngol*. 2017 Oct 31;2(6):373-379.
232. Treatment constraints for single dose external beam preoperative partial breast irradiation in early-stage breast cancer. Charaghvandi RK, Yoo S, van Asselen B, Rodrigues A, van den Bongard DHJG, Horton JK. *Clin Transl Radiat Oncol*. 2017 Sep 8;6:7-14.
233. Fast online replanning for interfraction rotation correction in prostate radiotherapy. Kontaxis C, Bol GH, Kerkmeijer LGW, Lagendijk JJW, Raaymakers BW. *Med Phys*. 2017 Oct;44(10):5034-5042.

234. Challenges in MR-only seed localization for postimplant dosimetry in permanent prostate brachytherapy. Zijlstra F, Moerland MA, van der Voort van Zyp JRN, Noteboom JL, Viergever MA, Seevinck PR. *Med Phys*. 2017 Oct;44(10):5051-5060.
235. Renal Cell Carcinoma: Alternative Nephron-Sparing Treatment Options for Small Renal Masses, a Systematic Review. Prins FM, Kerkmeijer LGW, Pronk AA, Vonken EPA, Meijer RP, Bex A, Barendrecht MM. *J Endourol*. 2017 Oct;31(10):963-975.
236. Costs and clinical outcomes of implant placement during ablative surgery and postponed implant placement in curative oral oncology: a five-year retrospective cohort study. Wetzels JGH, Meijer GJ, Koole R, Adang EM, Merckx MAW, Speksnijder CM. *Clin Oral Implants Res*. 2017 Nov;28(11):1433-1442.
237. Adaptive bulk motion exclusion for improved robustness of abdominal magnetic resonance imaging. Stemkens B, Benkert T, Chandarana H, Bittman ME, Van den Berg CAT, Lagendijk JJW, Sodickson DK, Tijssen RHN, Block KT. *NMR Biomed*. 2017 Nov;30(11).
238. Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases. van der Velden JM, Peters M, Verlaan JJ, Versteeg AL, Zhang L, Tsao M, Danjoux C, Barnes E, van Vulpen M, Chow E, Verkooijen HM. *Int J Radiat Oncol Biol Phys*. 2017 Nov 15;99(4):859-866.
239. Dosimetric feasibility of the hybrid Magnetic Resonance Imaging (MRI)-linac System (MRL) for brain metastases: The impact of the magnetic field. Tseng CL, Eppinga W, Seravalli E, Hackett S, Brand E, Ruschin M, Lee YK, Atenafu EG, Sahgal A. *Radiother Oncol*. 2017 Nov;125(2):273-279.
240. Salvage brachytherapy for radiorecurrent prostate cancer: Searching for safety and success. Peters M, Moerland MA, van der Voort van Zyp JRN. *Brachytherapy*. 2017 Nov - Dec;16(6):1099-1100.
241. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Raaymakers BW, Jürgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte ANTJ, van Asselen B, de Boer JCJ, Bluemink JJ, Hackett SL, Moerland MA, Woodings SJ, Wolthaus JWH, van Zijp HM, Philippens MEP, Tijssen R, Kok JGM, de Groot-van Breugel EN, Kiekebosch I, Meijers LTC, Nomden CN, Sikkes GG, Doornaert PAH, Eppinga WSC, Kasperts N, Kerkmeijer LGW, Tersteeg JHA, Brown KJ, Pais B, Woodhead P, Lagendijk JJW. *Phys Med Biol*. 2017 Nov 14;62(23).
242. Feasibility of MR-only proton dose calculations for prostate cancer radiotherapy using a commercial pseudo-CT generation method. Maspero M, van den Berg CAT, Landry G, Belka C, Parodi K, Seevinck PR, Raaymakers BW, Kurz C. *Phys Med Biol*. 2017 Nov 21;62(24):9159-9176.
243. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Maenhout M, Peters M, van Vulpen M, Moerland MA, Meijer RP, van den Bosch MAAJ, Nguyen PL, Frank SJ, van der Voort van Zyp JRN. *Technol Cancer Res Treat*. 2017 Dec;16(6):1194-1201.
244. Magnetic resonance imaging in precision radiation therapy for lung cancer. Bainbridge H, Salem A, Tijssen RHN, Dubec M, Wetscherek A, Van Es C, Belderbos J, Faivre-Finn C, McDonald F; lung tumour site group of the international Atlantic MR-Linac Consortium. *Transl Lung Cancer Res*. 2017 Dec;6(6):689-707.
245. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtwängler R, Verschuur AC, Vujanic GM, Leuschner I, Brok J, Rube C, Smets AM, Janssens GO, Godzinski J, Ramirez-Villar GL, de Camargo B, Segers H, Collini P, Gessler M, Bergeron C, Spreafico F, Graf N; International Society of Paediatric Oncology — Renal Tumour Study Group (SIOP-RTSG). *Nat Rev Urol*. 2017 Dec;14(12):743-752.
246. Superior target delineation for stereotactic body radiotherapy of bone metastases from renal cell carcinoma on MRI compared to CT. Prins FM, van der Velden JM, Gerlich AS, Kotte ANTJ, Eppinga WSC, Kasperts N, Verlaan JJ, Pameijer FA, Kerkmeijer LGW. *Ann Palliat Med*. 2017 Dec;6(Suppl 2):S147-S154.
247. Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer. Laan JJ, van Lonkhuijzen LRCW, van Os RM, Tytgat KM, Dávila Fajardo R, Pieters BR, Stalpers LJA, Westerveld GH. *Gynecol Oncol*. 2017 Dec;147(3):684-689.
248. Non-rigid CT/CBCT to CBCT registration for online external beam radiotherapy guidance. Zachiu C, de Senneville BD, Tijssen RHN, Kotte ANTJ, Houweling AC, Kerkmeijer LGW, Lagendijk JJW, Moonen CTW, Ries M. *Phys Med Biol*. 2017 Dec 29;63(1).
249. Three times sequential chemoradiotherapy for in-field relapse in a patient with limited disease small cell lung cancer; a Case Report. Marnix J.A. Rasing, Rick A.J. Heyne, Franz, M. Schramel, Sherif Y.El Sharouni. *Internal Medicine Review*, Volume 3, Issue 5, 1-6, 2017.
250. Total reference air kerma can accurately predict isodose surface volumes in cervix cancer brachytherapy, A multicenter study. K.S. Nkiwane, E. Andersen, J. Champoudry, A. de Leeuw, J. Swamidias, J. Lindegaard, R. Pötter, C. Kirisits, K. Tanderup, *Brachytherapy*, 16 (2017) 1184-1191.

251. MRI-based transfer function determination for the assessment of implant safety. Tokaya JP, Raaijmakers AJE, Luijten PR, Bakker JF, van den Berg CAT. *Magn Reson Med*. 2017 Dec;78(6):2449-2459.

2016

252. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE. *J Clin Oncol*. 2016 Jan 20;34(3):235-43.
253. Evolution of motion uncertainty in rectal cancer: implications for adaptive radiotherapy. Kleijnen JP, van Asselen B, Burbach JP, Intven M, Philippens ME, Reerink O, Lagendijk JJ, Raaymakers BW. *Phys Med Biol*. 2016 Jan 7;61(1):1-11.
254. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Kirchheiner K, Nout RA, Lindegaard JC, Haie-Meder C, Mahantshetty U, Segedin B, Jürgenliemk-Schulz IM, Hoskin PJ, Rai B, Dörr W, Kirisits C, Bentzen SM, Pötter R, Tanderup K; EMBRACE Collaborative Group. *Radiother Oncol*. 2016 Jan;118(1):160-6.
255. Inter-observer agreement of MRI-based tumor delineation for preoperative radiotherapy boost in locally advanced rectal cancer. Burbach JP, Kleijnen JP, Reerink O, Seravalli E, Philippens ME, Schakel T, van Asselen B, Raaymakers BW, van Vulpen M, Intven M. *Radiother Oncol*. 2016 Feb;118(2):399-407.
256. Local specific absorption rate in brain tumors at 7 tesla. Restivo MC, van den Berg CA, van Lier AL, Polders DL, Raaijmakers AJ, Luijten PR, Hoogduin H. *Magn Reson Med*. 2016 Jan;75(1):381-9.
257. Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma. Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJM, van den Brekel MW, Breunis WB, Chang YC, Davila Fajardo R, Dunaway D, Gajdosova E, Gaze MN, Gupta S, Hartley B, Kremer LCM, van Lennep M, Levitt GA, Mandeville HC, Pieters BR, Saeed P, Smeele LE, Strackee SD, Ronckers CM, Caron HN, van Santen HM, Merks JHM. *Eur J Cancer*. 2016 Feb;54:1-10.
258. Rectal dose constraints for salvage iodine-125 prostate brachytherapy. Peters M, Hoekstra CJ, van der Voort van Zyp JR, Westendorp H, van de Pol SM, Moerland MA, Maenhout M, Kattenvilder R, van Vulpen M. *Brachytherapy*. 2016 Jan-Feb;15(1):85-93.
259. Quantification of intra-fraction motion in breast radiotherapy using supine magnetic resonance imaging. van Heijst TC, Philippens ME, Charaghvandi RK, den Hartogh MD, Lagendijk JJ, van den Bongard HJ, van Asselen B. *Phys Med Biol*. 2016 Feb 7;61(3):1352-70.
260. Performance of a cylindrical diode array for use in a 1.5 T MR-linac. Houweling AC, de Vries JH, Wolthaus J, Woodings S, Kok JG, van Asselen B, Smit K, Bel A, Lagendijk JJ, Raaymakers BW. *Phys Med Biol*. 2016 Feb 7;61(3).
261. In vivo electric conductivity of cervical cancer patients based on B_1^+ maps at 3T MRI. E, de Boer P, van Lier AL, Remis RF, Stalpers LJ, Westerveld GH, Nederveen AJ, van den Berg CA, Crezee J. *Phys Med Biol*. 2016 Feb 21;61(4).
262. Minimizing the magnetic field effect in MR-linac specific QA-tests: the use of electron dense materials. van Zijp HM, van Asselen B, Wolthaus JW, Kok JM, de Vries JH, Ishakoglu K, Beld E, Lagendijk JJ, Raaymakers BW. *Phys Med Biol*. 2016 Feb 7;61(3).
263. Fast 3D isotropic imaging of the aortic vessel wall by application of 2D spatially selective excitation and a new way of inversion recovery for black blood imaging. Mooiweer R, Sbrizzi A, El Aidi H, Eikendal AL, Raaijmakers A, Visser F, van den Berg CA, Leiner T, Luijten PR, Hoogduin H. *Magn Reson Med*. 2016 Feb;75(2):547-55.
264. Diffusion-weighted MRI for Early Prediction of Treatment Response on Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer: A Feasibility Study. Jacobs L, Intven M, van Lelyveld N, Philippens M, Burbach M, Seldenrijk K, Los M, Reerink O. *Ann Surg*. 2016 Mar;263(3):522-8.
265. Adaptive planning strategy for high dose rate prostate brachytherapy—a simulation study on needle positioning errors. Borot de Battisti M, Denis de Senneville B, Maenhout M, Hautvast G, Binnekamp D, Lagendijk JJ, van Vulpen M, Moerland MA. *Phys Med Biol*. 2016 Mar 7;61(5):2177-95.
266. An optimization framework to maximize signal-to-noise ratio in simultaneous multi-slice body imaging. Stemkens B, Sbrizzi A, Andreychenko AA, Crijs SP, Lagendijk JJ, van den Berg CA, Tijssen RH. *NMR Biomed*. 2016 Mar;29(3):275-83.

267. The fractionated dipole antenna: A new antenna for body imaging at 7 Tesla. Raaijmakers AJ, Italiaander M, Voogt IJ, Luijten PR, Hoogduin JM, Klomp DW, van den Berg CA. *Magn Reson Med*. 2016 Mar;75(3):1366-74.
268. Enhancement of Magnetic Resonance Imaging with Metasurfaces. Slobozhanyuk AP, Poddubny AN, Raaijmakers AJ, van den Berg CA, Kozachenko AV, Dubrovina IA, Melchakova IV, Kivshar YS, Belov PA. *Adv Mater*. 2016 Mar 2;28(9):1832-8.
269. Automated daily breath hold stability measurements by real-time imaging in radiotherapy of breast cancer. de Boer HC, van den Bongard DJ, van Asselen B. *Radiother Oncol*. 2016 Apr;119(1):61-4.
270. Feasibility of measuring thermoregulation during RF heating of the human calf muscle using MR based methods. Simonis FF, Petersen ET, Lagendijk JJ, van den Berg CA. *Magn Reson Med*. 2016 Apr;75(4):1743-51.
271. Correlation of human papillomavirus status with apparent diffusion coefficient of diffusion-weighted MRI in head and neck squamous cell carcinomas. Driessen JP, van Bommel AJ, van Kempen PM, Janssen LM, Terhaard CH, Pameijer FA, Willems SM, Stegeman I, Grolman W, Philippens ME. *Head Neck*. 2016 Apr;38 Suppl 1:E613-8.
272. Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. Peters M, van der Voort van Zyp JR, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, Maenhout M, Kattenvilder R, Verkooijen HM, van Rossum PS, Ahmed HU, Shah TT, Emberton M, van Vulpen M. *Radiother Oncol*. 2016 Apr;119(1):104-10.
273. 4D MR imaging using robust internal respiratory signal. Hui C, Wen Z, Stemkens B, Tijssen RH, van den Berg CA, Hwang KP, Beddar S. *Phys Med Biol*. 2016 May 7;61(9):3472-87.
274. Automated daily breath hold stability measurements by real-time imaging in radiotherapy of breast cancer. de Boer HC, van den Bongard DJ, van Asselen B. *Radiother Oncol*. 2016 Apr;119(1):61-4.
275. Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, Nout RA; EMBRACE Collaborative Group. *Int J Radiat Oncol Biol Phys*. 2016 APR 1;94(5):1088-98.
276. Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society. Janssens GO, Langendijk JA, Terhaard CH, Doornaert PA, van den Ende P, de Jong MA, Takes RP, Span PN, Kaanders JH. *Radiother Oncol*. 2016 May;119(2):213-20.
277. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. Peters M, van der Voort van Zyp JR, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, Maenhout M, Kattenvilder R, Verkooijen HM, van Rossum PS, Ahmed HU, Shah TT, Emberton M, van Vulpen M. *Brachytherapy*. 2016 May-Jun;15(3):296-305.
278. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH. *J Nucl Med*. 2016 May;57(5):691-700.
279. PREDICT: model for prediction of survival in localized prostate cancer. Kerkmeijer LG, Monninkhof EM, van Oort IM, van der Poel HG, de Meerleer G, van Vulpen M. *World J Urol*. 2016 Jun;34(6):789-95.
280. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long-term follow-up study. Schoot RA, Theunissen EA, Slater O, Lopez-Yurda M, Zuur CL, Gaze MN, Chang YC, Mandeville HC, Gains JE, Rajput K, Pieters BR, Davila Fajardo R, Talwar R, Caron HN, Balm AJ, Dreschler WA, Merks JH. *Clin Otolaryngol*. 2016 Jun;41(3):276-83.
281. MRI-guided prostate adaptive radiotherapy - A systematic review. McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A; MR-Linac consortium. *Radiother Oncol*. 2016 Jun;119(3):371-80.
282. Patients' and Health Care Providers' Opinions on a Supportive Health App During Breast Cancer Treatment: A Qualitative Evaluation. Young-Afat DA, van Gils CH, Bruinvels DJ, van der Pol CC, Witkamp AJ, Sijtsma S, Jonasse Y, Bijlsma RM, Ausems MG, Bos AM, van den Bongard DH, Verkooijen HM. *JMIR Cancer*. 2016 Jun 7;2(1).
283. Image-driven, model-based 3D abdominal motion estimation for MR-guided radiotherapy. Stemkens B, Tijssen RH, de Senneville BD, Lagendijk JJ, van den Berg CA. *Phys Med Biol*. 2016 Jul 21;61(14):5335-55.
284. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy. Heethuis SE, van Rossum PS, Lips IM, Goense L, Voncken FE,

- Reerink O, van Hillegersberg R, Ruurda JP, Philippens ME, van Vulpen M, Meijer GJ, Lagendijk JJ, van Lier AL. *Radiother Oncol.* 2016 Jul;120(1).
285. MRI sequences for the detection of individual lymph nodes in regional breast radiotherapy planning. van Heijst TC, van Asselen B, Pijnappel RM, Cloos-van Balen M, Lagendijk JJ, van den Bongard D, Philippens ME. *Br J Radiol.* 2016 Jul;89(1063).
286. Within the next five years, adaptive hypofractionation will become the most common form of radiotherapy. van Vulpen M, Wang L. *Med Phys.* 2016 Jul;43(7):3941.
287. Consequences of air around an ionization chamber: Are existing solid phantoms suitable for reference dosimetry on an MR-linac? Hackett SL, van Asselen B, Wolthaus JW, Kok JG, Woodings SJ, Lagendijk JJ, Raaymakers BW. *Med Phys.* 2016 Jul;43(7):3961.
288. Image-driven, model-based 3D abdominal motion estimation for MR-guided radiotherapy. Stemkens B, Tijssen RH, de Senneville BD, Lagendijk JJ, van den Berg CA. *Phys Med Biol.* 2016 Jul 21;61(14).
289. The development of the MRI linac system for online MRI-guided radiotherapy: a clinical update. Lagendijk JJ, van Vulpen M, Raaymakers BW. *J Intern Med.* 2016 Aug;280(2):203-8.
290. Element decoupling of 7T dipole body arrays by EBG metasurface structures: Experimental verification. Hurshkainen AA, Derzhavskaya TA, Glybovski SB, Voogt IJ, Melchakova IV, van den Berg CAT, Raaijmakers AJE. *J Magn Reson.* 2016 Aug;269:87-96.
291. Hyperthermia treatment planning for cervical cancer patients based on electrical conductivity tissue properties acquired in vivo with EPT at 3 T MRI. Balidemaj E, Kok HP, Schooneveldt G, van Lier AL, Remis RF, Stalpers LJ, Westerveld H, Nederveen AJ, van den Berg CA, Crezee J. *Int J Hyperthermia.* 2016 Aug;32(5):558-68.
292. Effectiveness and cost-utility of a guided self-help exercise program for patients treated with total laryngectomy: protocol of a multi-center randomized controlled trial. Jansen F, Cnossen IC, Eerenstein SE, Coupé VM, Witte BI, van Uden-Kraan CF, Doornaert P, Braunius WW, De Bree R, Hardillo JA, Honings J, Halmos GB, Leemans CR, Verdonck-de Leeuw IM. *BMC Cancer.* 2016 Aug 2;16:580.
293. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. *Clin Cancer Res.* 2016 Aug 15;22(16):4215-24.
294. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, Hoogerbrugge N, Willemsen MA. *Clin Genet.* 2016 Aug;90(2):105-17.
295. Increase of intracellular cisplatin levels and radiosensitization by ultrasound in combination with microbubbles. Lammertink BHA, Bos C, van der Wurff-Jacobs KM, Storm G, Moonen CT, Deckers R. *J Control Release.* 2016 Sep 28;238:157-165.
296. Edema and Seed Displacements Affect Intraoperative Permanent Prostate Brachytherapy Dosimetry. Westendorp H, Nuver TT, Hoekstra CJ, Moerland MA, Minken AW. *Int J Radiat Oncol Biol Phys.* 2016 Sep 1;96(1):197-205.
297. A geometrical shift results in erroneous appearance of low frequency tissue eddy current induced phase maps. Mandija S, van Lier AL, Katscher U, Petrov PI, Neggers SF, Luijten PR, van den Berg CA. *Magn Reson Med.* 2016 Sep;76(3):905-12.
298. Image guided Adaptive Brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome. Tanderup K, Lindegaard JC, Kirisits C, Haie-Meder C, Kirchheiner K, de Leeuw A, Jürgenliemk-Schulz I, Van Limbergen E, Pötter R. *Radiother Oncol.* 2016 Sep;120(3):365-369.
299. Monte Carlo study of the impact of a magnetic field on the dose distribution in MRI-guided HDR brachytherapy using Ir-192. Beld E, Seevinck PR, Lagendijk JJ, Viergever MA, Moerland MA. *Phys Med Biol.* 2016 Sep 21;61(18):6791-6807.
300. Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III. Van der Meer FS, Schramel FM, VAN Vulpen M, El Sharouni SY. *Anticancer Res.* 2016 Sep;36(9):4673-6.
301. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Mazon R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Šegedin B, Mahantshetty U, Hoskin P, Jürgenliemk-Schulz I, Kirisits C, Lindegaard JC, Dörr W, Haie-Meder C, Tanderup K, Pötter R; EMBRACE collaborative group. *Radiother Oncol.* 2016 Sep;120(3):412-419.
302. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Tanderup K, Fokdal LU, Sturdza A, Haie-

- Meder C, Mazon R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, Dörr W, Bentzen SM, Kirisits C, Lindegaard JC, Pötter R. *Radiother Oncol.* 2016 Sep;120(3):441-446.
303. Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients. Westerveld H, de Leeuw A, Kirchheiner K, Dankulchai P, Oosterveld B, Oinam A, Hudej R, Swamidas J, Lindegaard J, Tanderup K, Pötter R, Kirisits C; EMBRACE Collaborative Group. *Radiother Oncol.* 2016 Sep;120(3):420-427.
304. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazon R, Petric P, Šegedin B, Jürgenliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, Kirchheiner K, Kirisits C, Tanderup K, Lindegaard JC. *Radiother Oncol.* 2016 Sep;120(3):428-433.
305. A volumetric analysis of GTV_D and CTV_{HR} as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE). Jastaniyah N, Yoshida K, Tanderup K, Lindegaard JC, Sturdza A, Kirisits C, Šegedin B, Mahantshetty U, Rai B, Jürgenliemk-Schulz IM, Haie-Meder C, Banerjee S, Pötter R; EMBRACE Collaborative Group. *Radiother Oncol.* 2016 Sep;120(3):404-411.
306. Noninvasive Electric Current Induction for Low-Frequency Tissue Conductivity Reconstruction: Is It Feasible With a TMS-MRI Setup? Mandija S, Petrov PI, Neggers SFW, Luijten PR, van den Berg CAT. *Tomography.* 2016 Sep;2(3):203-214.
307. Dipole antennas for ultrahigh-field body imaging: a comparison with loop coils. Raaijmakers AJ, Luijten PR, van den Berg CA. *NMR Biomed.* 2016 Sep;29(9):1122-30.
308. Vaginal dose de-escalation in image guided adaptive brachytherapy for locally advanced cervical cancer. Mohamed S, Lindegaard JC, de Leeuw AA, Jürgenliemk-Schulz I, Kirchheiner K, Kirisits C, Pötter R, Tanderup K. *Radiother Oncol.* 2016 Sep;120(3):480-485.
309. Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III. Van der Meer FS, Schramel FM, VAN Vulpen M, El Sharouni SY. *Anticancer Res.* 2016 Sep;36(9):4673-6.
310. H MRS in the human spinal cord at 7 T using a dielectric waveguide transmitter, RF shimming and a high density receive array Henning A, Koning W, Fuchs A, Raaijmakers A, Bluemink JJ, van den Berg CA, Boer VO, Klomp DW. *NMR Biomed.* 2016 Sep;29(9):1231-9.
311. A geometrical shift results in erroneous appearance of low frequency tissue eddy current induced phase maps. Mandija S, van Lier AL, Katscher U, Petrov PI, Neggers SF, Luijten PR, van den Berg CA. *Magn Reson Med.* 2016 Sep;76(3):905-12.
312. Long-Term Health-Related Quality of Life in Patients With Rectal Cancer After Preoperative Short-Course and Long-Course (Chemo) Radiotherapy. Wiltink LM, Nout RA, van der Voort van Zyp JR, Ceha HM, Fiocco M, Meershoek-Klein Kranenbarg E, Marinelli AW, van de Velde CJ, Marijnen CA. *Clin Colorectal Cancer.* 2016 Sep;15(3).
313. Accessory Left Gastric Artery from Left Hepatic Artery is a Potential Risk for Radioembolization Complications. Lam MG, Borggreve AS, Landman AJ, Vissers CM, De Jong CD, Monnikhof EM, Prince JF. *Cardiovasc Intervent Radiol.* 2016 Sep;39(9):1367-8.
314. PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure. Shah TT, Peters M, Kanthabalan A, McCartan N, Fatola Y, van der Voort van Zyp J, van Vulpen M, Freeman A, Moore CM, Arya M, Emberton M, Ahmed HU. *Prostate Cancer Prostatic Dis.* 2016 Sep;19(3):311-6.
315. Influence of FDG-PET on primary nodal target volume definition for head and neck carcinomas. van Egmond SL, Piscaer V, Janssen LM, Stegeman I, Hobbelink MG, Grolman W, Terhaard CH. *Acta Oncol.* 2016 Sep - Oct;55(9-10):1099-1106.
316. The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. Kerkmeijer LG, Fuller CD, Verkooijen HM, Verheij M, Choudhury A, Harrington KJ, Schultz C, Sahgal A, Frank SJ, Goldwein J, Brown KJ, Minsky BD, van Vulpen M; MR-Linac Consortium Clinical Steering Committee. *Front Oncol.* 2016 Oct 13;6:215.
317. Fiber Bragg gratings-based sensing for real-time needle tracking during MR-guided brachytherapy. Borot de Battisti M, Denis de Senneville B, Maenhout M, Lagendijk JJ, van Vulpen M, Hautvast G, Binnekamp D, Moerland MA. *Med Phys.* 2016 Oct;43(10):5288.

318. The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Peerlings J, Troost EG, Nelemans PJ, Cobben DC, de Boer JC, Hoffmann AL, Beets-Tan RG. *Radiology*. 2016 Oct;281(1):86-98.
319. Post-treatment Surveillance for Stage I and II Non-small Cell Lung Cancer: Impact on Clinical Outcome. Karzijn R, Alberts L, Kelder JC, Hofman FN, El Sharouni SY, Kastelijin EA, Schramel FM. *Anticancer Res*. 2016 Oct;36(10):5413-5418.
320. Dielectric waveguides for ultrahigh field magnetic resonance imaging. Bluemink JJ, Raaijmakers AJ, Koning W, Andreychenko A, Rivera DS, Luijten PR, Klomp DW, van den Berg CA. *Magn Reson Med*. 2016 Oct;76(4):1314-24.
321. Improving the arterial input function in dynamic contrast enhanced MRI by fitting the signal in the complex plane. Simonis FF, Sbrizzi A, Beld E, Lagendijk JJ, van den Berg CA. *Magn Reson Med*. 2016 Oct;76(4):1236-45.
322. Comparing conventional Radiotherapy with stereotactic body radiotherapy in patients with spinal metastases: study protocol for a randomized controlled trial following the cohort multiple randomized controlled trial design. van der Velden JM, Verkooijen HM, Seravalli E, Hes J, Gerlich AS, Kasperts N, Eppinga WS, Verlaan JJ, van Vulpen M. *BMC Cancer*. 2016 Nov 21;16(1):909.
323. MR-based measurements and simulations of the magnetic field created by a realistic transcranial magnetic stimulation (TMS) coil and stimulator. Mandija S, Petrov PI, Neggers SF, Luijten PR, van den Berg CA. *NMR Biomed*. 2016 Nov;29(11):1590-1600.
324. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M. *World J Urol*. 2016 Nov;34(11):1521-1531.
325. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Swartz JE, Pothen AJ, Wegner I, Smid EJ, Swart KM, de Bree R, Leenen LP, Grolman W. *Oral Oncol*. 2016 Nov;62:28-33.
326. Validated guidelines for tumor delineation on magnetic resonance imaging for laryngeal and hypopharyngeal cancer. Jager EA, Ligtenberg H, Caldas-Magalhaes J, Schakel T, Philippens ME, Pameijer FA, Kasperts N, Willems SM, Terhaard CH, Raaijmakers CP. *Acta Oncol*. 2016 Nov;55(11):1305-1312.
327. Development and clinical introduction of automated radiotherapy treatment planning for prostate cancer. Winkel D, Bol GH, Van Asselen B, Hes J, Scholten V, Kerkmeijer LGW, Raaymakers BW. *Phys Med Biol*. 2016;61(24):8587-95.
328. Radiation to the Gastric Fundus Increases the Risk of Anastomotic Leakage After Esophagectomy. Goense L, van Rossum PS, Ruurda JP, van Vulpen M, Mook S, Meijer GJ, van Hillegersberg R. *Ann Thorac Surg*. 2016 Dec;102(6):1798-1804.
329. Automatic Coronary Artery Calcium Scoring on Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association with Traditional Cardiovascular Risk Factors. Gernaat SA, Išgum I, de Vos BD, Takx RA, Young-Afat DA, Rijnberg N, Grobbee DE, van der Graaf Y, de Jong PA, Leiner T, van den Bongard DH, Pignol JP, Verkooijen HM. *PLoS One*. 2016 Dec 9;11(12).
330. Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. Clement SC, Schouten-van Meeteren AY, Boot AM, Claahsen-van der Grinten HL, Granzen B, Sen Han K, Janssens GO, Michiels EM, van Trotsenburg AS, Vandertop WP, van Vuurden DG, Kremer LC, Caron HN, van Santen HM. *J Clin Oncol*. 2016 Dec 20;34(36):4362-4370.
331. Adverse effect of smoking on prognosis in human papillomavirus-associated oropharyngeal carcinoma. Liskamp CP, Janssens GO, Bussink J, Melchers WJ, Kaanders JH, Verhoef CG. *Head Neck*. 2016 Dec;38(12):1780-1787.
332. Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer. Cobben DC, de Boer HC, Tijssen RH, Rutten EG, van Vulpen M, Peerlings J, Troost EG, Hoffmann AL, van Lier AL. *Technol Cancer Res Treat*. 2016 Dec;15(6).
333. Comparative cost-effectiveness of focal and total salvage ¹²⁵I brachytherapy for recurrent prostate cancer after primary radiotherapy. Peters M, Piena MA, Steuten LM, van der Voort van Zyp JR, Moerland MA, van Vulpen M. *J Contemp Brachytherapy*. 2016 Dec;8(6):484-491.
334. Physically constrained voxel-based penalty adaptation for ultra-fast IMRT planning. Wahl N, Bangert M, Kamerling CP, Ziegenhein P, Bol GH, Raaymakers BW, Oelfke U. *J Appl Clin Med Phys*. 2016;17(4):6117.

2015

335. Perineal recurrence of prostate cancer six years after trans-perineal brachytherapy. Eppinga W, Vijverberg P, Moerland R, Brand E, van der Voort van Zyp J, Noteboom J, van Vulpen M. *J Contemp Brachytherapy*. 2015 Jan;6(4):386-8.
336. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. Van der Heiden, van der Loo M, de Munck L, Sonke GS, van Dalen T, van Diest PJ, van den Bongard HJ, Peeters PH, Rutgers EJ. *Eur J Cancer* 2015;51(8):915-21.
337. First results of the preoperative accelerated partial breast irradiation trial (PAPBI) trial. Van der Leij F, Bosma SC, van e Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, Bourcier C, Garbay JR, Foukakis T, Lekberg T, van den Bongard DH, van Vliet-Vroegindewij C, Bartelijnk H Rutgers EJ, Elkhuizen PH. *Radiother Oncol* 2015;114(3):322-7.
338. GTV delineation in supraglottic laryngeal carcinoma: interobserver agreement of CT versus CT-MR delineation. Jager EA, Kasperts N, Caldas-Magalhaes J, Philippens ME, Pameijer FA, Terhaard CH, Raaijmakers CP. *Radiat Oncol*. 2015 Jan 23;10:26.
339. Imaging of oesophageal cancer with FDG-PET/CT and MRI. van Rossum PS, van Lier AL, Lips IM, Meijer GJ, Reerink O, van Vulpen M, Lam MG, van Hillegersberg R, Ruurda JP. *Clin Radiol*. 2015 Jan;70(1):81-95.
340. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, van der Holt B, Aerts J, Hoogeman M. *Int J Radiat Oncol Biol Phys*. 2015 Feb 1;91(2):337-43.
341. Randomized controlled trial for pre-operative dose-escalation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Burbach JP, Verkooijen HM, Intven M, Kleijnen JP, Bosman ME, Raaymakers BW, van Grevenstein WM, Koopman M, Seravalli E, van Asselen B, Reerink O. *Trials*. 2015 Feb 22;16:58.
342. Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial. Rademakers SE, Hoogsteen IJ, Rijken PF, Terhaard CH, Doornaert PA, Langendijk JA, van den Ende P, van der Kogel AJ, Bussink J, Kaanders JH. *Head Neck*. 2015 Feb;37(2):171-6.
343. Towards adaptive IMRT sequencing for the MR-linac. Kontaxis C, Bol GH, Lagendijk JJ, Raaymakers BW. *Phys Med Biol*. 2015 Mar 21;60(6):2493-509.
344. Compensating for magnetic field inhomogeneity in multigradient-echo-based MR thermometry. Simonis FF, Petersen ET, Bartels LW, Lagendijk JJ, van den Berg CA. *Magn Reson Med*. 2015 Mar;73(3):1184-9.
345. Optimizing 4-dimensional magnetic resonance imaging data sampling for respiratory motion analysis of pancreatic tumors. Stemkens B, Tijssen RH, de Senneville BD, Heerkens HD, van Vulpen M, Lagendijk JJ, van den Berg CA. *Int J Radiat Oncol Biol Phys*. 2015 Mar 1;91(3):571-8.
346. The accuracy of target delineation in laryngeal and hypopharyngeal cancer. Caldas-Magalhaes J, Kooij N, Ligtenberg H, Jager EA, Schakel T, Kasperts N, Pameijer FA, Terhaard CH, Janssen LM, van Diest PJ, Philippens ME, Raaijmakers CP. *Acta Oncol*. 2015;54(8):1181-7.
347. Diffusion-weighted imaging in head and neck squamous cell carcinomas: A systematic review. Driessen JP, van Kempen PM, van der Heijden GJ, Philippens ME, Pameijer FA, Stegeman I, Terhaard CH, Janssen LM, Grolman W. *Head Neck*. 2015;Mar;37(3):440-8.
348. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P. *Int J Radiat Oncol Biol Phys*. 2015 Mar 1;91(3):530-9.
349. Radiotherapy for extensive stage small-cell lung cancer - Authors' reply. Slotman BJ, van Tinteren H, Praag JO, Kneijens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S. *Lancet*. 2015 Apr 4;385(9975):1292-3.
350. Quality of life during 5 years after stereotactic radiotherapy in stage I non-small cell lung cancer. Ubels RJ, Mokhles S, Andrinopoulou ER, Braat C, van der Voort van Zyp NC, Aluwini S, Aerts JG, Nuyttens JJ. *Radiat Oncol*. 2015 Apr 22;10:98.
351. Feasibility of electric property tomography of pelvic tumors at 3T. Balidemaj E, van Lier AL, Crezee H, Nederveen AJ, Stalpers LJ, van den Berg CA. *Magn Reson Med*. 2015 Apr;73(4):1505-13.
352. No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. Wiltink LM, Nout RA, Fiocco M, Meershoek-

- Klein Kranenburg E, Jürgenliemk-Schulz IM, Jobsen JJ, Nagtegaal ID, Rutten HJ, van de Velde CJ, Creutzberg CL, Marijnen CA. *J Clin Oncol*. 2015 May 20;33(15):1640-6.
353. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. van Rossum PS, van Lier AL, van Vulpen M, Reerink O, Lagendijk JJ, Lin SH, van Hillegersberg R, Ruurda JP, Meijer GJ, Lips IM. *Radiother Oncol*. 2015 May;115(2):163-70.
354. Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, Kerkmeijer LG, Pameijer FA, Veldhuis WB, van der Voort van Zyp JR, Pos FJ, Heijmink SW, Kalisvaart R, Teertstra HJ, Dinh CV, Ghobadi G, van der Heide UA. *Radiother Oncol*. 2015 May;115(2):186-90.
355. Treatment of T3 laryngeal cancer in the Netherlands: a national survey. Doornaert P, Terhaard CH, Kaanders JH; Dutch National Platform Radiotherapy Head and Neck Cancer. *Radiat Oncol*. 2015 Jun 26;10:134.
356. Interobserver variation among pathologists for delineation of tumor on H&E-sections of laryngeal and hypopharyngeal carcinoma. How good is the gold standard? Jager EA, Willems SM, Schakel T, Kooij N, Slootweg PJ, Philippens ME, Caldas-Magalhaes J, Terhaard CH, Raaijmakers CP. *Acta Oncol*. 2015; Jun 13:1-5.
357. Acute toxicity after a diverting stoma and spacer prior to chemoradiation in locally advanced rectal cancer. van der Voort van Zyp JR, Ceha HM, Niehe V, Marinelli AW, Putter H, Marijnen CA. *Radiother Oncol*. 2015 Jul;116(1):107-11.
358. On-line 3D motion estimation using low resolution MRI. Glitzner M, de Senneville BD, Lagendijk JJ, Raaymakers BW, Crijs SP. *Phys Med Biol*. 2015 Aug 21;60(16).
359. A review of the clinical experience in pulsed dose rate brachytherapy. Balgobind BV, Koedooder K, Ordoñez Zúñiga D, Dávila Fajardo R, Rasch CR, Pieters BR. *Br J Radiol*. 2015;88(1055): Aug 20. Review.
360. CSI-EPT: A Contrast Source Inversion Approach for Improved MRI-Based Electric Properties Tomography. Balidemaj E, van den Berg CA, Trinks J, van Lier AL, Nederveen AJ, Stalpers LJ, Crezee H, Remis RF. *IEEE Trans Med Imaging*. 2015 Sep;34(9).
361. Improved MRI-Based Electric Properties Tomography. Balidemaj E, van den Berg CA, Trinks J, van Lier AL, Nederveen AJ, Stalpers LJ, Crezee H, Remis RF. *CSI-EPT: A Contrast Source Inversion Approach for IEEE Trans Med Imaging*. 2015 Sep;34(9):1788-96.
362. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA. *Eur J Cancer*. 2015 Sep;51(13):1742-50.
363. A new methodology for inter- and intrafraction plan adaptation for the MR-linac. Kontaxis C, Bol GH, Lagendijk JJ, Raaymakers BW. *Phys Med Biol*. 2015 Oct 7;60(19):7485-97.
364. Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection. Kastelijns EA, El Sharouni SY, Hofman FN, Van Putte BP, Monnikhof EM, Van Vulpen M, Schramel FM. *Anticancer Res*. 2015 Oct;35(10):5607-14.
365. What Can Be Expected on Irradiated Skin? A Dermatologic Focus on Acute and Chronic Radiotherapeutic Effects, Treatment, and Benign Dermatoses. Cuperus E, Albregts M, Toonstra J. *Skinmed*. 2015 Oct 1;13(5):361-74. eCollection 2015.
366. The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. Dankbaar JW, Sniijders TJ, Robe PA, Seute T, Eppinga W, Hendrikse J, De Keizer B. *J Neurooncol*. 2015 Oct;125(1):167-75.
367. An automated, fast and accurate registration method to link stranded seeds in permanent prostate implants. Westendorp H, Nuver TT, Moerland MA, Minken AW. *Phys Med Biol*. 2015 Oct 21;60(20):N391-403.
368. An automated optimization tool for high-dose-rate (HDR) prostate brachytherapy with divergent needle pattern. Borot de Battisti M, Maenhout M, Denis de Senneville B, Hautvast G, Binnekamp D, Lagendijk JJ, van Vulpen M, Moerland MA. *Phys Med Biol*. 2015 Oct 7;60(19):7567-83.
369. Post-lumpectomy CT-guided tumor bed delineation for breast boost and partial breast irradiation: Can additional pre- and postoperative imaging reduce interobserver variability? DEN Hartogh MD, Philippens ME, VAN Dam IE, Kleynen CE, Tersteeg RJ, Kotte AN, VAN Vulpen M, VAN Asselen B, VAN DEN Bongard DH. *Oncol Lett*. 2015 Nov;10(5):2795-2801.
370. Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis. Cox MC, Kusters JM, Gidding CE, Schieving JH, van Lindert EJ, Kaanders JH, Janssens GO. *Radiat Oncol*. 2015 Nov 24;10:241.

371. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Oerlemans S, Putter H, Verhoeven-Adema KW, Nijman HW, Creutzberg CL. *Int J Radiat Oncol Biol Phys*. 2015 Nov 15;93(4):797-809.
372. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE). Yoshida K, Jastaniyah N, Sturdza A, Lindegaard J, Segedin B, Mahantshetty U, Rai B, Jürgenliemk-Schulz I, Haie-Meder C, Sasaki R, Pötter R. *Int J Radiat Oncol Biol Phys*. 2015 Nov 15;93(4):788-96
373. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints. Peters M, van der Voort van Zyp J, Hoekstra C, Westendorp H, van de Pol S, Moerland M, Maenhout M, Kattenvilder R, van Vulpen M. *Radiother Oncol*. 2015 Nov;117(2):262-9.
374. On-line MR imaging for dose validation of abdominal radiotherapy. Glitzner M, Crijns SP, de Senneville BD, Kontaxis C, Prins FM, Lagendijk JJ, Raaymakers BW. *Phys Med Biol*. 2015 Nov 21;60(22):8869-83.
375. RF peak power reduction in CAIPIRINHA excitation by interslice phase optimization. Sbrizzi A, Poser BA, Tse DH, Hoogduin H, Luijten PR, van den Berg CA. *NMR Biomed*. 2015 Nov;28(11):1393-401.
376. Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer. Intven M, Monnikhof EM, Reerink O, Philippens ME. *Acta Oncol*. 2015 Nov;54(10):1729-36.
377. MRI-guided single fraction ablative radiotherapy for early-stage breast cancer: a brachytherapy versus volumetric modulated arc therapy dosimetry study. Charaghvandi RK, den Hartogh MD, van Ommen AM, de Vries WJ, Scholten V, Moerland MA, Philippens ME, Schokker RI, van Vulpen M, van Asselen B, van den Bongard DH. *Radiother Oncol*. 2015 Dec;117(3):477-82.
378. Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. Lim K, Erickson B, Jürgenliemk-Schulz IM, Gaffney D, Creutzberg CL, Viswanathan A, Portelance L, Beriwal S, Wolfson A, Bosch W, De Los Santos J, Yashar C, Jhingran A, Varia M, El Naqa I, King B, Fyles A. *Pract Radiat Oncol*. 2015 Nov-Dec;5(6).
379. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE. *N Engl J Med*. 2015 Dec 24;373(26):2499-511.
380. Quality assurance in MR image guided adaptive brachytherapy for cervical cancer: Final results of the EMBRACE study dummy run. Kirisits C, Federico M, Nkiwane K, Fidarova E, Jürgenliemk-Schulz I, de Leeuw A, Lindegaard J, Pötter R, Tanderup K. *Radiother Oncol*. 2015 Dec;117(3):548-54.
381. Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer. Ramlov A, Kroon PS, Jürgenliemk-Schulz IM, De Leeuw AA, Gormsen LC, Fokdal LU, Tanderup K, Lindegaard JC. *Acta Oncol*. 2015;54(9):1567-73.
382. Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts. Alberts L, El Sharouni SY, Hofman FN, Van Putte BP, Tromp E, Van Vulpen M, Kastelijns EA, Schramel FM. *Anticancer Res*. 2015 Dec;35(12):6773-9.
383. Safety of a scout dose preceding hepatic radioembolization with Ho microspheres. Prince JF, Van Rooij R, Bol GH, De Jong HWAM, Van Den Bosch MAAJ, Lam MGEH. *J Nucl Med* 2015;56(6):817-23.
384. Compensating for the impact of non-stationary spherical air cavities on IMRT dose delivery in transverse magnetic fields. Bol GH, Lagendijk JJW, Raaymakers BW. *Phys Med Biol* 2015;60(2):755-68.
385. Dosimetric feasibility of intensity modulated proton therapy in a transverse magnetic field of 1.5 T. Hartman J, Kontaxis C, Bol GH, Frank SJ, Lagendijk JJW, Van Vulpen M, Raaymakers BW. *Phys Med Biol* 2015;60(15):5955-69.
386. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Ben J Slotman, Harm van Tinteren, John O Praag, Joost L Knegjens, Sherif Y El Sharouni, Matthew Hatton, Astrid Keijser, Corinne Faivre-Finn*, Suresh Senan. *Lancet* 2015; 385: 36–42.
387. Three times sequential chemoradiotherapy for in-field relapse in a patient with limited disease small cell lung cancer; a Case Report. Marnix J.A. Rasing, Rick A.J. Heyne, Franz, M. Schramel, Sherif Y. El Sharouni. *Internal Medicine Review*, Volume 3, Issue 5, 1-6.